HETEROCYCLICAL COMPOUNDS FOR INVERTEBRATIC PEST CONTROL

Description

[0001] The invention relates to compounds of formula I wherein R 1< is H, OH, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -halocycloalkyl, C 1 -C 5 -alkoxy, C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl, C 1 -C 4 -alkyl-C 3 -C 6 -cycloalkyl, C 1 -C 4 -alkyl-C 3 -C 6 -halocycloalkyl, which groups are unsubstituted, or partially or fully substituted with R 11< ; or C(=N-R 11< )R 12< , C(O)R 11a< ; R 11< is CN, NO 2 , NR 12< R 13< , C(O)NH 2 , C(S)NH 2 , C(O)OH, OR 14< , Si(CH 3 ) 3 ; C 1 -C 6 -alkyl; C 1 -C 6 -haloalkyl; C 2 -C 3 -alkenyl; C 2 -C 6 -haloalkenyl; C 2 -C 6 -alkynyl; C 2 -C 6 -haloalkynyl; C 3 -C 4 -cycloalkyl-C 1 -C 2 -alkyl, which ring is unsubstituted or substituted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with halogen, C 1 -C 3 -haloalkyl, and / or CN; R 11a< is NR 12< R 13< , C(O)NH 2 , C(S)NH 2 , C(O)OH, OR 14< , Si(CH 3 ) 3 ; C 1 -C 6 -haloalkyl; C 2 -C 6 -alkenyl; C 2 -C 6 -haloalkenyl; C 2 -C 6 -alkynyl; C 2 -C 6 -haloalkynyl; C 3 -C 6 -cycloalkyl-C 1 -C 2 -alkyl, which ring is unsubstituted or substituted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with halogen, C 1 -C 3 -haloalkyl, and / or CN; R 12< , R 13< are independently from each other H, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy, C 1 -C 4 -haloalkyl, C 3 -C 3 -cycloalkyl, C(O)-C 1 -C 4 -alkyl, C(O)-C 1 -C 4 -haloalkyl, C(O)-C 3 -C 4 -cycloalkyl, C(O)-C 3 -C 4 -halocycloalkyl, C(O)NR 121< R 131< , S(O) m -C 1 -C 4 -haloalkyl, S(O) m -C 3 -C 6 -cycloalkyl, S(O) m -C 3 -C 6 -halocycloalkyl; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with halogen, C 1 -C 3 -haloalkyl, and / or CN; R 121< and R 131< are independently from each other H, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -halocycloalkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkoxy; C 1 -C 4 -alkyl-phenyl, C 1 -C 4 -alkyl-3-6-membered hetaryl, phenyl, 3- to 6-membered heterocyclyl or 5- or 6-membered hetaryl, which rings are unsubstituted or substituted with halogen, C 1 -C 3 -haloalkyl, and / or CN; or R 121< and R 131< together with the nitrogen atom they are bound to form a 3-6 membered saturated, partially or fully unsaturated heterocycle, which may further contain 1 or 2 heteroatoms ring members selected from N, O and S, wherein S may be oxidized, which heterocycle is unsubstituted or substituted with halogen, C 1 -C 3 -haloalkyl, and / or CN; or R 12< and R 13< together with the nitrogen atom they are bound to form a 3-6 membered saturated, partially unsaturated, or aromatic heterocycle, which may contain 1 or 2 additional heteroatoms selected from N, O and S, wherein S may be partially or fully oxidized, and which is unsubstituted or substituted with oxo, and / or R 3< ; or R 12< and R 13< together with the nitrogen atom they are bound to form a group N=S(=O)R 14a< R 14b< , wherein R 14a< and R 14b< are defined as R 14< ; m is 0, 1, or 2; R 14< is H, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -halocycloalkyl, C 3 -C 4 -cycloalkyl-C 1 -C 2 -alkyl, C 3 -C 4 -halocycloalkyl-C 1 -C 2 -alkyl, C(O)-C 1 -C 4 -alkyl, C(O)-C 1 -C 4 -haloalkyl, C(O)-C 3 -C 4 -cycloalkyl, C(O)-C 3 -C 4 -halocycloalkyl, or phenyl which is unsubstituted or partially or fully substituted with R 3< ; R 2< is CH3; Xis CH, CR 3< , or N; R 3< is halogen, CN, NO 2 , C 1 -C 4 -alkyl, C 3 -C 6 -cycloalkyl, C 1 -C 6 -haloalkyl, C 3 -C 6 -halocycloalkyl, OR 14< , S(O) m -R 14< ; which are unsubstituted or substituted with R 3a< ; R 3a< halogen, CN, NO 2 , C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, OR 15< , C 1 -C 4 -haloalkoxy, C 3 -C 4 -cycloalkyl, C 3 -C 4 -halocycloalkyl, S(O) m -C 1 -C 4 -alkyl, S(O) m -C 1 -C 4 -haloalkyl, S(O) m -C 3 -C 4 -cycloalkyl, S(O) m -C 3 -C 4 -halocycloalkyl; n is 2; R 4< is C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 1 -C 6 -haloalkyl, C 3 -C 6 -halocycloalkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -haloalkenyl, C 2 -C 4 -alkynyl, each unsubstituted or partially or fully substituted with R 41< ; S(O) m -C 1 -C 4 -alkyl, S(O) m -C 1 -C 4 -haloalkyl, S(O) m -C 3 -C 6 -cycloalkyl, S(O) m -C 3 -C 6 -halocycloalkyl, NR 12< R 13< , C(O)NR 12< R 13< , C(O)OR 14< , 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R 3< ; and wherein R3 is in positions 3 and 5; R 41< is H, OR 15< , NR 12< R 13< , C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C(O)-C 1 -C 4 -alkyl, C(O)-C 1 -C 4 -haloalkyl, C(O)-C 3 -C 4 -cycloalkyl, C(O)-C 3 -C 4 -halocycloalkyl, C(O)OR 15< , C(O)NR 121< R 131< ; S(O) m -C 1 -C 4 -haloalkyl, S(O) m -C 3 -C 4 -cycloalkyl, S(O) m -C 3 -C 4 -halocycloalkyl; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl; which cyclic R 41< groups are unsubstituted or partially or fully substituted with halogen, C 1 -C 3 -haloalkyl, and / or CN; R 15< is H, C 1 -C 4 -alkyl, or C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C 1 -C 6 -halocycloalkyl, which carbon chains are unsubstituted or partially or fully substituted with R 11< ; or 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R 3< ; R 5< is H, halogen, CN, OR 15< , C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkoxy, C 3 -C 6 -cycloalkyl, C 1 -C 4 -alkyl-phenyl, C 1 -C 4 -alkyl-3-6-membered hetaryl, phenyl, 3- to 6-membered heterocyclyl or 5- or 6-membered hetaryl, which rings are unsubstituted or substituted with halogen, C 1 -C 3 -haloalkyl, and / or CN; Q, Q 1< , and Q 2< are, independently from each other, N or CR 6< , wherein no more than one of Q, Q 1< , and Q 2< is N; R 6< is H, halogen, CN, OR 14< , NR 12< R 13< , C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -halocycloalkyl, C(O)NR 12< R 13< , C(O)OR 14< , S(O) m -C 1 -C 4 -alkyl, S(O) m -C 1 -C 4 -haloalkyl, S(O) m -C 3 -C 6 -cycloalkyl, S(O) m -C 3 -C 6 -halocycloalkyl; and the N-oxides, stereoisomers and agriculturally or veterinarily acceptable salts thereof.

[0002] The references to methods of treatment in the subsequent paragraphs of this description are to be interpreted as references to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy (or for diagnosis).

[0003] The invention also provides agricultural compositions comprising at least one compound of formula I, a stereoisomer thereof and / or an agriculturally acceptable salt thereof and at least one liquid and / or solid carrier, especially at least one inert liquid and / or solid agriculturally acceptable carrier.

[0004] The invention also provides a veterinary composition comprising at least one compound of formula I, a stereoisomer thereof and / or a veterinarily acceptable salt thereof and at least one liquid and / or solid carrier, especially at least one inert veterinarily liquid and / or solid acceptable carrier.

[0005] The invention also provides a method for controlling invertebrate pests which method comprises treating the pests, their food supply, their habitat or their breeding ground or a cultivated plant, plant propagation materials (such as seed), soil, area, material or environment in which the pests are growing or may grow, or the materials, cultivated plants, plant propagation materials (such as seed), soils, surfaces or spaces to be protected from pest attack or infestation with a pesticidally effective amount of a compound of formula I or a salt thereof as defined herein. The invention also relates to plant propagation material, in particular seed, comprising at least one compound of formula I and / or an agriculturally acceptable salt thereof.

[0006] The invention further relates to a method for treating or protecting an animal from infestation or infection by parasites which comprises bringing the animal in contact with a parasiticidally effective amount of a compound of formula I or a veterinarily acceptable salt thereof. Bringing the animal in contact with the compound I, its salt or the veterinary composition of the invention means applying or administering it to the animal.

[0007] WO 2017 / 192385, WO2021 / 068179, WO2021 / 069575, and WO2021 / 037614 describe structurally closely related active compounds. These compounds are mentioned to be useful for combating invertebrate pests.

[0008] Nevertheless, there remains a need for highly effective and versatile agents for combating invertebrate pests. It is therefore an object of the invention to provide compounds having a good pesticidal activity and showing a broad activity spectrum against a large number of different invertebrate pests, especially against difficult to control pests, such as insects.

[0009] It has been found that these objects can be achieved by compounds of formula I as depicted and defined below, and by their stereoisomers, salts, tautomers and N-oxides, in particular their agriculturally acceptable salts.

[0010] Compounds I with R 1< being different from H can be obtained by reaction of a compound II in which R 1< = H with a suitable reagent III. In formula III, R has the same meaning as R 1< in formula I, respectively, and Y is a nucleophilic leaving group, such as a halide, mesylate, or tosylate, preferably Br or Cl. The reaction can be effected under conditions known from literature.

[0011] This transformation is usually carried out at temperatures from -10°C to +110°C, preferably from 0°C to 25°C, in an inert solvent and in the presence of a base [cf. WO 2002100846 and S. M. Somagond, Heterocycl. Commun. 2017, 317].

[0012] The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of III, based on II.

[0013] Compounds II can be obtained by reaction of an amino compound IV with a carboxylic acid V

[0014] This transformation is usually carried out at temperatures of from -20°C to 50°C, preferably from 0°C to 25°C, in an inert solvent, in the presence of a peptide coupling reagent and optionally in the presence of a base [cf. A. El-Faham, Chem. Rev. 2011, 6557], or in two steps by preparation of an intermediate acyl chloride from V under conditions known from literature, e.g. by reaction with SOCl 2 or oxalyl chloride in dimethylformamide (DMF) (cf. Schaefer et al, Organic Syntheses 1929, 32), followed by reaction with IV in the presence of a base, optionally under Schotten-Baumann conditions (Baumann, Chem. Ber. 1886, 3218). Suitable peptide coupling reagents are, e.g., dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride, or chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate, which are commonly used together with catalytic, stoichiometric, excess amounts of additives, such as 1-hydroxybenzotriazole, 1-hydroxy-7-aza-benzotriazole, 4-(dime-thylamino)pyridine, and / or 1-methylimidazole.

[0015] Suitable solvents are halogenated hydrocarbons, such as dichloromethane (DCM) or 1,2-dichloroethane, ethers, such as diethylether, tetrahydrofurane (THF) or 1,4-dioxane, or high-boiling solvents such as DMF, preferably DCM or DMF, or in aqueous media.

[0016] Suitable bases are, in general, inorganic compounds, such as alkali metal and alkaline earth metal hydroxides, such as LiOH, NaOH, KOH, or Ca(OH) 2 , alkali metal and alkaline earth metal carbonates, such as Na 2 CO 3 , K 2 CO 3 , or CS 2 CO 3 , alkali metal bicarbonates, such as NaHCO 3 , or organic bases, for example tertiary amines, such as triethylamine, diisopropylethylamine, N-methylpiperidine, or basic aromatic rings, such as pyridine, 2,4,6-collidine, 2,6-lutidine, or 4-(di-methylamino)pyridine, or bicyclic amines, such as 1,8-diazabicylo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), or 1,4-diazabicyclo[2.2.2]octane (DABCO).

[0017] Particular preference is given to triethylamine, diisopropylethylamine, and NaOH.

[0018] The bases are generally employed in stoichiometric or excess amounts; however, they can also be used in catalytic amounts or, if appropriate, as the solvent.

[0019] The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of IV based on V.

[0020] Compounds IV can be obtained by reductive amination of a compound VI.

[0021] This transformation is usually carried out at temperatures of from 0°C to 130°C, preferably from 20°C to 70°C, generally in alcoholic and / or aqueous media and in the presence of a reagent and a reducing agent [cf. WO2021037614]. Suitable solvents are alcohols, such as methanol, ethanol, n-propanol, 2-propanol, or n-butanol, or water, preferably methanol. It is also possible to use mixtures of the aforementioned solvents. Suitable reagents are ammonium acetate (NH 4 Ac), ammonium formate, NH 4 OH, NH 4 Cl, ammonia, or primary amines R 1< NH 2 . Suitable reducing agents are NaBH 3 CN, sodium triacetoxyborohydride, or NaBH 4 . Preference is given to ammonium acetate and NaBH 3 CN, resp.

[0022] Compounds VI are obtainable from compounds VII in a two-step sequence consisting of Stille coupling of VII with an alkoxyalkenylstannane such as VIII followed by hydrolysis of the resulting enol ether moiety to the ketone VI.

[0023] The Stille coupling reaction is usually carried out at temperatures from 50°C to 150°C, preferably from 70°C to 120°C, in an inert solvent in the presence of one or more catalysts and optionally in the presence of one or more additives and a base [cf. H. Lin et al., Bioorg Med Chem Lett 2010, 679]. Suitable solvents are aromatic hydrocarbons such as toluene, o-, m-, p-xylene, and mesitylene, or ethers such as THF and 1,4-dioxane, preferably toluene or 1,4-dioxane. It is also possible to use mixtures of the aforementioned solvents. Suitable catalysts are palladium complexes, such as tetrakis(triphenylphosphine)palladium, tris(dibenzylideneacetone)dipalladium, palladium diacetate, dichloro-bis(triphenylphosphine)palladium, and [1,1'-bis(diphenylphos-phino)ferrocene]dichloropalladium, preferably dichlorobis(triphenylphosphine)palladium. Further suitable optional catalysts are common ligands, such as dicyclohexyl[2',4',6'-tris(propan-2-yl)[1,1'-biphenyl]-2-yl]phosphine or triphenylphosphine. Suitable additives are, in general, inorganic compounds, such as cesium fluoride and cuprous iodide. The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of VIII, based on VII.

[0024] The hydrolysis is usually carried out at temperatures from -20°C to 40°C, preferably from 0°C to 25°C, in aqueous acidic media containing aqueous HCl at concentrations between 0.5M and 3M and optionally containing an organic solvent such as acetonitrile, acetone, THF, or methanol (cf H. Lin et al., Bioorg. Med. Chem. Lett. 2010, 679).

[0025] Alternatively, compounds VI wherein Q 1< =N and Q 2< =Q=CH can be obtained by reaction of 1-(3-chloropyrazin-2-yl)ethanone with 1H-1,2,4-triazol-5-ones in the presence of a base, such as Cs 2 CO 3 or K 2 CO 3 , in an aprotic polar solvent, such as acetonitrile, DMF, or dimethyl sulfoxide (DMSO), at temperatures from 0°C to 150°C, preferably from 60°C to 120°C, in analogy to WO2017055185 and WO2020178789. While 1-(3-chloropyrazin-2-yl)ethanone is known from WO2021259997, the preparation of 1H-1,2,4-triazol-5-ones is well described in the literature, e.g. in WO2017205709.

[0026] Compounds VII are obtainable from triazolones IX. In formula X, group Z is a leaving group, e.g. a halide, such as I, Br, and Cl, or a sulfonate, such as triflate or mesylate.

[0027] This transformation is usually carried out at temperatures from 0°C to 120°C, preferably from 25°C to 70°C, in an inert solvent and in the presence of a base [cf. A. R. Nesaragi et al., Bioorg. Med. Chem. Lett. 2021, 127984]. Suitable solvents are halogenated hydrocarbons, such as DCM, 1,2-dichloroethane, or chloroform, ethers, such as diethylether, tert-butylmethylether, dioxane, or THF, nitriles, such as acetonitrile or propionitrile, and polar aprotic solvents, such as DMSO, DMF, or dimethylacetamide (DMA), preferably acetonitrile. It is also possible to use mixtures of the aforementioned solvents.

[0028] Suitable bases are, in general, inorganic compounds, such as alkali metal carbonates, such as Na 2 CO 3 , K 2 CO 3 , or CS 2 CO 3 , alkali metal hydroxides, such as NaOH or KOH, or organic bases, e.g. tertiary amines such as triethylamine or diisopropylethylamine. Preference is given to K 2 CO 3 . The bases are generally employed in equimolar amounts; however, they can also be used in excess or, if appropriate, as solvent.

[0029] The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of X, based on IX.

[0030] Triazolones IX are obtainable from compounds XI by reaction with diphenylphosphoryl azide or similar reagent (e.g. employing a mixture of trimethylsilyl azide and propanephosphonic acid anhydride) using an aromatic hydrocarbon, such as benzene, toluene, xylenes, or mesitylene, as a solvent, and a tertiary amine, such as triethylamine or diisopropylethylamine, as a base, at temperatures from 0°C to 130°C, preferably between 25°C and 80°C, as known from literature (cf. J. W. Lyga, Synth. Commun. 1986, 163).

[0031] Compounds XI are obtainable from hydrazines XII by condensation with the aldehyde or ketone moiety of a 1,2-dicarbonyl compound XIII.

[0032] This transformation is usually carried out at temperatures from 0°C to 110°C, preferably from 25°C to 90°C, in a protic solvent, such as methanol, ethanol, 2-propanol, water, or a mixture of the aforementioned solvents, preferably in water, and optionally in the presence of an acid, such as acetic acid or HCl (c.f. Q. Yang et al., Org. Process Res. Dev. 2019, 2122).

[0033] The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of XIII, based on XII.

[0034] Compounds XII are either commercially available, e.g., CAS 63286-28-2 and 117087-45-3, or can be prepared from commercially available materials under conditions known from literature.

[0035] Alternatively, compounds I can be obtained from 4-methoxybenzyl- (PMB-)substituted compounds I (R 4< =PMB) in a two-step sequence involving removal of the PMB group by treatment with an acid, such as TFA (e.g., WO2007134862) or with an oxidizing agent such as diammonium cerium(IV) nitrate (CAN, e.g., WO2017167832), followed by reaction of the intermediate (INT) using the reagents and reaction conditions as described above for the synthesis of compounds VII from compounds IX. The same two-step sequence can also be used to obtain compounds I from the corresponding compounds I wherein R 4< is 2,4-dimethoxybenzyl (DMB) or 2,4,6-trimethoxybenzyl (TMB). Intermediate compounds (INT) are novel. The variables in formula (INT) are as defined for formula I.

[0036] The reaction mixtures are worked up in a customary manner, e.g. by mixing with water, extracting with an appropriate organic solvent, separating the phases and, if appropriate, chromatographic purification of the crude products. Some of the intermediates and end products are obtained in the form of colourless or slightly brownish viscous oils which are purified or freed from volatile components under reduced pressure and at moderately elevated temperature. If the intermediates and end products are obtained as solids, purification can also be carried out by recrystallization or digestion.

[0037] If individual compounds I cannot be obtained by the routes described above, they can be prepared by derivatization of other compounds I.

[0038] However, if the synthesis yields mixtures of isomers, a separation is generally not necessarily required since in some cases the individual isomers can be interconverted during work-up for use or during application (for example under the action of light, acids or bases). Such conversions may also take place after use, for example in the treatment of plants in the treated plant, or in the pest to be controlled.

[0039] The organic moieties groups mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members. The prefix C n -C m indicates in each case the possible number of carbon atoms in the group.

[0040] The term "partially or fully substituted" by a radical means that in general the group is substituted with same or different radicals.

[0041] The term "halogen" denotes in each case fluorine, bromine, chlorine, or iodine, in particular fluorine, chlorine, or bromine.

[0042] The term "alkyl" as used herein and in the alkyl moieties of alkylamino, alkylcarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl and alkoxyalkyl denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms. Examples of an alkyl group are methyl (Me), ethyl (Et), n-propyl (n-Pr), iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, and 1-ethyl-2-methylpropyl.

[0043] The term "haloalkyl" as used herein and in the haloalkyl moieties of haloalkylcarbonyl, haloalkoxycarbonyl, haloalkylthio, haloalkylsulfonyl, haloalkylsulfinyl, haloalkoxy and haloalkoxyalkyl, denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms. Preferred haloalkyl moieties are selected from C 1 -C 4 -haloalkyl, more preferably from C 1 -C 3 -haloalkyl or C 1 -C 2 -haloalkyl, in particular from C 1 -C 2 -fluoroalkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, and the like.

[0044] The term "alkoxy" as used herein denotes in each case a straight-chain or branched alkyl group which is bonded via an oxygen atom and has usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. Examples of an alkoxy group are methoxy, ethoxy, n-propoxy, iso-propoxy, n-butyloxy, 2-butyloxy, iso-butyloxy, tert.-butyloxy, and the like.

[0045] The term "alkoxyalkyl" as used herein refers to alkyl usually comprising 1 to 10, frequently 1 to 4, preferably 1 to 2 carbon atoms, wherein 1 carbon atom carries an alkoxy radical usually comprising 1 to 4, preferably 1 or 2 carbon atoms as defined above. Examples are CH 2 OCH 3 , CH 2 -OC 2 H 5 , 2-(methoxy)ethyl, and 2-(ethoxy)ethyl.

[0046] The term "haloalkoxy" as used herein denotes in each case a straight-chain or branched alkoxy group having from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms, in particular fluorine atoms. Preferred haloalkoxy moieties include C 1 -C 4 -haloalkoxy, in particular C 1 -C 2 -fluoroalkoxy, such as fluoromethoxy, difluoromethoxy, trifluoro-methoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoro-ethoxy, 2,2dichloro-2-fluorethoxy, 2,2,2-trichloroethoxy, penta-fluoroethoxy and the like.

[0047] The term "alkylthio "(alkylsulfanyl: S-alkyl)" as used herein refers to a straight-chain or branched saturated alkyl group having 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= C 1 -C 4 -alkylthio), more preferably 1 to 3 carbon atoms, which is attached via a sulfur atom.

[0048] The term "haloalkylthio" as used herein refers to an alkylthio group as mentioned above wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and / or iodine.

[0049] The term "alkylsulfinyl" (alkylsulfoxyl: S(=O)-alkyl), as used herein refers to a straight-chain or branched saturated alkyl group (as mentioned above) having 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= C 1 -C 4 -alkylsulfinyl), more preferably 1 to 3 carbon atoms bonded through the sulfur atom of the sulfinyl group at any position in the alkyl group.

[0050] The term "haloalkylsulfinyl" as used herein refers to an alkylsulfinyl group as mentioned above wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and / or iodine.

[0051] The term "alkylsulfonyl" (S(=O) 2 -alkyl) as used herein refers to a straight-chain or branched saturated alkyl group having 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= C 1 -C 4 -alkylsulfonyl), preferably 1 to 3 carbon atoms, which is bonded via the sulfur atom of the sulfonyl group at any position in the alkyl group.

[0052] The term "haloalkylsulfonyl" as used herein refers to an alkylsulfonyl group as mentioned above wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and / or iodine.

[0053] The term "alkylcarbonyl" refers to an alkyl group as defined above, which is bonded via the carbon atom of a carbonyl group (C=O) to the remainder of the molecule.

[0054] The term "haloalkylcarbonyl" refers to an alkylcarbonyl group as mentioned above, wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and / or iodine. The term "alkoxycarbonyl" refers to an alkylcarbonyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.

[0055] The term "haloalkoxycarbonyl" refers to an alkoxycarbonyl group as mentioned above, wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and / or iodine.

[0056] The term "alkenyl" as used herein denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. vinyl, allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl, methallyl (2-methylprop-2-en-1-yl), 2-buten-1-yl, 3-buten-1-yl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1-methylbut-2-en-1-yl, 2-ethylprop-2-en-1-yl and the like.

[0057] The term "haloalkenyl" as used herein refers to an alkenyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.

[0058] The term "alkynyl" as used herein denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. ethynyl, propargyl (2-propyn-1-yl), 1-propyn-1-yl, 1-methylprop-2-yn-1-yl), 2-butyn-1-yl, 3-butyn-1-yl, 1-pentyn-1-yl, 3-pentyn-1-yl, 4-pentyn-1-yl, 1-methylbut-2-yn-1-yl, 1-ethylprop-2-yn-1-yl and the like.

[0059] The term "haloalkynyl" as used herein refers to an alkynyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.

[0060] The term "cycloalkyl" as used herein and in the cycloalkyl moieties of cycloalkoxy and cycloalkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 or from 3 to 6 carbon atoms, such as cyclopropyl (cC 3 H 5 ), cyclobutyl (cC 4 H 7 ), cyclopentyl (cC 5 H 9 ), cyclohexyl (cC 6 H 11 ), cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl or cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0061] The term "halocycloalkyl" as used herein and in the halocycloalkyl moieties of halocycloalkoxy and halocycloalkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 C atoms or 3 to 6 C atoms, wherein at least one, e.g. 1, 2, 3, 4 or 5 of the hydrogen atoms, are replaced by halogen, in particular by fluorine or chlorine. Examples are 1- and 2-fluorocyclopropyl, 1,2-, 2,2- and 2,3-difluorocyclopropyl, 1,2,2-trifluorocyclopropyl, 2,2,3,3-tetrafluorocyclpropyl, 1- and 2-chlorocyclopropyl, 1,2-, 2,2- and 2,3-dichlorocyclopropyl, 1,2,2-trichlorocyclopropyl, 2,2,3,3-tetrachlorocyclpropyl, 1-,2- and 3-fluorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-difluorocyclopentyl, 1-,2- and 3-chlorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-dichlorocyclopentyl and the like.

[0062] The term "halocycloalkenyl" as used herein and in the halocycloalkenyl moieties of halocyclo-alkenyloxy and halocycloalkenylthio denotes in each case a monocyclic singly unsaturated non-aromatic radical having usually from 3 to 10, e.g. 3 or 4 or from 5 to 10 carbon atoms, preferably from 3- to 8 carbon atoms, wherein at least one, e.g. 1, 2, 3, 4 or 5 of the hydrogen atoms, are replaced by halogen, in particular by fluorine or chlorine. Examples are 3,3-difluorocyclopropen-1-yl and 3,3-dichlorocyclopropen-1-yl.

[0063] The term "cycloalkenylalkyl" refers to a cycloalkenyl group as defined above which is bonded via an alkyl group, such as a C 1 -C 5 -alkyl group or a C 1 -C 4 -alkyl group, in particular a methyl group (= cycloalkenylmethyl), to the remainder of the molecule.

[0064] The term "carbocycle" or "carbocyclyl" includes in general a 3- to 12-membered, preferably a 3- to 8-membered or a 5- to 8-membered, more preferably a 5- or 6-membered mono-cyclic, non-aromatic ring comprising 3 to 12, preferably 3 to 8 or 5 to 8, more preferably 5 or 6 carbon atoms. Preferably, the term "carbocycle" covers cycloalkyl and cycloalkenyl groups as defined above.

[0065] The term "heterocycle" or "heterocyclyl" includes in general 3- to 12-membered, preferably 3-to 6-membered, in particular 6-membered monocyclic heterocyclic non-aromatic radicals. The heterocyclic non-aromatic radicals usually comprise 1, 2, 3, 4 or 5, preferably 1, 2 or 3 heteroatoms selected from N, O, and S as ring members, wherein S-atoms as ring members may be present as S, SO, or SO 2 . Examples of 5- or 6-membered heterocyclic radicals comprise saturated or unsaturated, non-aromatic heterocyclic rings, such as oxiranyl, oxetanyl, thietanyl, thietanyl-S-oxid (S-oxothietanyl), thietanyl-S-dioxid (S-dioxothiethanyl), pyrrolidinyl, pyrrolinyl, pyrazolinyl, tetrahydrofuranyl, dihydrofuranyl, 1,3-dioxolanyl, thiolanyl, S-oxothiolanyl, S-dioxo-thiolanyl, dihydrothienyl, S-oxodihydrothienyl, S-dioxodihydrothienyl, oxazolidinyl, oxazolinyl, thiazolinyl, oxathiolanyl, piperidinyl, piperazinyl, pyranyl, dihydropyranyl, tetrahydropyranyl, 1,3- and 1,4-dioxanyl, thiopyranyl, S.oxothiopyranyl, S-dioxothiopyranyl, dihydrothiopyranyl, S-oxodihydrothiopyranyl, S-dioxodihydrothiopyranyl, tetrahydrothiopyranyl, S-oxotetrahydrothiopyranyl, S-dioxotetrahydrothiopyranyl, morpholinyl, thiomorpholinyl, S-oxothiomorpholinyl, S-dioxothio-morpholinyl, thiazinyl and the like. Examples for heterocyclic ring also comprising 1 or 2 carbonyl groups as ring members comprise pyrrolidin-2-onyl, pyrrolidin-2,5-dionyl, imidazolidin-2-onyl, oxazolidin-2-onyl, thiazolidin-2-only, and the like.

[0066] The term "hetaryl" includes monocyclic 5- or 6-membered heteroaromatic radicals comprising as ring members 1, 2, 3 or 4 heteroatoms selected from N, O, and S. Examples of 5- or 6-membered heteroaromatic radicals include pyridyl, i.e. 2-, 3-, or 4-pyridyl, pyrimidinyl, i.e. 2-, 4- or 5-pyrimidinyl, pyrazinyl, pyridazinyl, i.e. 3- or 4-pyridazinyl, thienyl, i.e. 2- or 3-thienyl, furyl, i.e. 2- or 3-furyl, pyrrolyl, i.e. 2- or 3-pyrrolyl, oxazolyl, i.e. 2-, 3- or 5-oxazolyl, isoxazolyl, i.e. 3-, 4- or 5-isoxazolyl, thiazolyl, i.e. 2-, 3- or 5-thiazolyl, isothiazolyl, i.e. 3-, 4- or 5-isothiazolyl, pyrazolyl, i.e. 1-, 3-, 4- or 5-pyrazolyl, i.e. 1-, 2-, 4- or 5-imidazolyl, oxadiazolyl, e.g. 2- or 5-[1,3,4]oxadiazolyl, 4- or 5-(1,2,3-oxadiazol)yl, 3- or 5-(1,2,4-oxadiazol)yl, 2- or 5-(1,3,4-thiadiazol)yl, thiadiazolyl, e.g. 2- or 5-(1,3,4-thiadiazol)yl, 4- or 5-(1,2,3-thiadiazol)yl, 3- or 5-(1,2,4-thiadiazol)yl, triazolyl, e.g. 1H-, 2H- or 3H-1,2,3-triazol-4-yl, 2H-triazol-3-yl, 1H-, 2H-, or 4H-1,2,4-triazolyl and tetrazolyl, i.e. 1H- or 2H-tetrazolyl. The term "hetaryl" also includes bicyclic 8 to 10-membered heteroaromatic radicals comprising as ring members 1, 2 or 3 heteroatoms selected from N, O, and S, wherein a 5- or 6-membered heteroaromatic ring is fused to a phenyl ring or to a 5- or 6-membered heteroaromatic radical. Examples of a 5- or 6-membered heteroaromatic ring fused to a phenyl ring or to a 5- or 6-membered heteroaromatic radical include benzofuranyl, benzothienyl, indolyl, indazolyl, benzimidazolyl, benzoxathiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzoxazinyl, chinolinyl, isochinolinyl, purinyl, 1,8-naphthyridyl, pteridyl, pyrido[3,2-d]pyrimidyl or pyridoimidazolyl and the like. These fused hetaryl radicals may be bonded to the remainder of the molecule via any ring atom of 5- or 6-membered heteroaromatic ring or via a carbon atom of the fused phenyl moiety.

[0067] The terms "heterocyclylalkyl" and "hetarylalkyl" refer to heterocyclyl or hetaryl, respectively, as defined above which are bonded via a C 1 -C 5 -alkyl group or a C 1 -C 4 -alkyl group, in particular a methyl group (= heterocyclylmethyl or hetarylmethyl, respectively), to the remainder of the molecule.

[0068] The term "arylalkyl" and "phenylalkyl" refer to aryl as defined above and phenyl, respectively, which are bonded via C 1 -C 5 -alkyl group or a C 1 -C 4 -alkyl group, in particular a methyl group (= arylmethyl or phenylmethyl), to the remainder of the molecule, examples including benzyl, 1-phenylethyl, 2-phenylethyl, 2-phenoxyethyl etc.

[0069] The terms "alkylene", "cycloalkylene", "heterocycloalkylene", "alkenylene", "cycloalkenylene", "heterocycloalkenylene" and "alkynylene" refer to alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl and alkynyl as defined above, respectively, which are bonded to the remainder of the molecule, via two atoms, preferably via two carbon atoms, of the respective group, so that they represent a linker between two moieties of the molecule.

[0070] In a particular embodiment, the variables of the compounds of the formula I have the following meanings, these meanings, both on their own and in combination with one another, being particular embodiments of the compounds of the formula I.

[0071] Embodiments and preferred compounds of the invention for use in pesticidal methods and for insecticidal application purposes are outlined in the following paragraphs.

[0072] With respect to the variables, the particularly preferred embodiments of the intermediates correspond to those of the compounds of the formula I.

[0073] In a preferred embodiment, the compounds I are present in form of a mixture of compounds I.A and I.B, wherein compound I.A with S-configuration of the carbon atom neighboring the nitrogen is present in an amount of more than 50% by weight, in particular of at least 70% by weight, more particularly of at least 85% by weight, specifically of at least 90% by weight, based on the total weight of compounds I.A and I.B.

[0074] In one particularly preferred embodiment of the invention, the method comprises the step of contacting the plant, parts of it, its propagation material, the pests, their food supply, habitat or breeding grounds with a pesticidally effective amount of a compound of formula I.A.

[0075] Preferably R 1< is H, C 1 -C 6 -alkyl, C 3 -C 6 -alkynyl, C 3 -C 6 -cycloalkyl, or C 1 -C 4 -alkyl-C 3 -C 6 -cycloalkyl which rings are unsubstituted or substituted with CN or halogen.

[0076] R 2< is CH 3 , In formula I preferably Q 1< is N and Q and Q 2< are CH. Such compounds correspond to formula I.a.

[0077] In a preferred embodiment of formula I compounds Q is CH or CR 6< , particularly Q is CH.

[0078] In another embodiment Q is CR 6< , wherein R 6< is halogen, particularly CI. In another embodiment Q is CR 6< , wherein R 6< is C 1 -C 4 -alkyl, particularly CH 3 .

[0079] In another embodiment of formula I Q is C-R 6< , wherein R 6< is preferably H, halogen, or C 1 -C 4 -alkyl, particularly H or halogen. Such compounds correspond to formula I.b.

[0080] In a preferred embodiment of formula I.b Q 1< is N and Q 2< is CH.

[0081] in another preferred embodiment of formula I.b Q 1< and Q 2< are CH.

[0082] In formula I X is preferably CH or CR 3< , particularly CH. Such compounds correspond to Formula I.1

[0083] In another embodiment of formula I X is N. Such compounds correspond to formula I.2.

[0084] R 3< is preferably halogen, CN, C 1 -C 4 -haloalkyl, C 1 -C 4 -haloalkoxy, C 3 -C 4 -cycloalkyl unsubstituted or substituted with one or more CN, C 3 -C 4 -halocycloalkyl, S(O) m -C 1 -C 4 -alkyl, S(O) m -C 1 -C 4 -haloalkyl, S(O) m -C 3 -C 4 -cycloalkyl, S(O) m -C 3 -C 4 -halocycloalkyl, which rings are unsubstituted or substituted with CN or halogen. Index m in R 3< is preferably 2. Index n is 2.

[0085] R 3< groups stand in positions 3 and 5.

[0086] In another embodiment R 3< is preferably halogen, CN, C 1 -C 4 -haloalkyl, C 1 -C 4 -haloalkoxy, C 3 -C 4 -cycloalkyl, C 3 -C 4 -halocycloalkyl, S(O) m -C 1 -C 4 -alkyl, S(O) m -C 1 -C 4 -haloalkyl, S(O) m -C 3 -C 4 -cycloalkyl, S(O) m- C 3 -C 4 -halocycloalkyl, or S(O)m-R 14< , wherein R 14< is phenyl, which is partially substituted with R 3a< .

[0087] In another embodiment of formula I compounds R 3< is halogen, CN, NO 2 , C 1 -C 4 -alkyl, C 3 -C 6 -cycloalkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -halocycloalkyl, OR 14< , S(O) m -R 14< ; wherein rings are unsubstituted or substituted with R 11< .

[0088] R 4< is preferably C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, CH 2 C(O)NH-C 1 -C 6 -alkyl, S(O) m -C 1 -C 4 -alkyl, C 3 -C 6 -cycloalkyl, C 1 -C 4 -alkyl-C 3 -C 6 -cycloalkyl, or phenyl unsubstituted or substituted with one or more groups R 3< .

[0089] In another embodiment R 4< is preferably C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, CH 2 C(O)NH-C 1 -C 6 -alkyl, C 3 -C 3 -cycloalkyl, C 1 -C 4 -alkyl-C 3 -C 6 -cycloalkyl, or phenyl or 5- or 6-membered heteroaryl which (hetero)aryl groups are unsubstituted or substituted with one or more groups R 3< , wherein R 3< is preferably halogen, CN, or C 1 -C 3 -alkoxy.

[0090] R 5< is preferably H or C 1 -C 4 -alkyl, particularly H.

[0091] In particular with a view to their use, preference is given to the compounds of formula I compiled in the tables below, which compounds correspond to formulae I.1a*, I.1b*, I.1c*, I.1d*, I.2a*, I.2b*, I.2c*, and I.2d*. Each of the groups mentioned for a substituent in the tables is furthermore per se, independently of the combination in which it is mentioned, a particularly preferred aspect of the substituent in question. Table 1 Compounds of formula I.1a* in which R 4< is CH 2 CF 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 2 Compounds of formula I.1a* in which R 4< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 3 Compounds of formula I.1a* in which R 4< is C 2 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 4 Compounds of formula I.1a* in which R 4< is CH(CH 3 ) 2 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 5 Compounds of formula I.1a* in which R 4< is SO 2 CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 6 Compounds of formula I.1a* in which R 4< is C 6 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 7 Compounds of formula I.1a* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 8 Compounds of formula I.1a* in which R 4< is CH 2 OCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 9 Compounds of formula I.1a* in which R 4< is CH 2 C(=O)NHCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 10 Compounds of formula I.1a* in which R 4< is C(=O)OCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 11 Compounds of formula I.1a* in which R 4< is cC 3 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 12 Compounds of formula I.1a* in which R 4< is CH 2 -cC 3 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 13 Compounds of formula I.1b* in which R 4< is CH 2 CF 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 14 Compounds of formula I.1b* in which R 4< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 15 Compounds of formula I.1b* in which R 4< is C 2 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 16 Compounds of formula I.1b* in which R 4< is CH(CH 3 ) 2 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 17 Compounds of formula I.1b* in which R 4< is SO 2 CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 18 Compounds of formula I.1b* in which R 4< is C 6 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 19 Compounds of formula I.1b* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 20 Compounds of formula I.1b* in which R 4< is CH 2 OCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 21 Compounds of formula I.1b* in which R 4< is CH 2 C(=O)NHCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 22 Compounds of formula I.1b* in which R 4< is C(=O)OCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 23 Compounds of formula I.1b* in which R 4< is cC 3 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 24 Compounds of formula I.1b* in which R 4< is CH 2 -cC 3 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 25 Compounds of formula I.1c* in which R 4< is CH 2 CF 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 26 Compounds of formula I.1c* in which R 4< is CH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 27 Compounds of formula I.1c* in which R 4< is C 2 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 28 Compounds of formula I.1c* in which R 4< is CH(CH 3 ) 2 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 29 Compounds of formula I.1c* in which R 4< is SO 2 CH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 30 Compounds of formula I.1c* in which R 4< is C 6 H 5 , and R 6< is Cl, the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 31 Compounds of formula I.1c* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 32 Compounds of formula I.1c* in which R 4< is CH 2 OCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 33 Compounds of formula I.1c* in which R 4< is CH 2 C(=O)NHCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 34 Compounds of formula I.1c* in which R 4< is C(=O)OCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 35 Compounds of formula I.1c* in which R 4< is cC 3 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 36 Compounds of formula I.1c* in which R 4< is CH 2 -cC 3 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 37 Compounds of formula I.1c* in which R 4< is CH 2 CF 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 38 Compounds of formula I.1c* in which R 4< is CH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 39 Compounds of formula I.1c* in which R 4< is C 2 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 40 Compounds of formula I.1c* in which R 4< is CH(CH 3 ) 2 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 41 Compounds of formula I.1c* in which R 4< is SO 2 CH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 42 Compounds of formula I.1c* in which R 4< is C 6 H 5 , and R 6< is CH 3 , the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 43 Compounds of formula I.1c* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 44 Compounds of formula I.1c* in which R 4< is CH 2 OCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 45 Compounds of formula I.1c* in which R 4< is CH 2 C(=O)NHCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 46 Compounds of formula I.1c* in which R 4< is C(=O)OCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 47 Compounds of formula I.1c* in which R 4< is cC 3 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 48 Compounds of formula I.1c* in which R 4< is CH 2 -cC 3 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 49 Compounds of formula I.1d* in which R 4< is CH 2 CF 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 50 Compounds of formula I.1d* in which R 4< is CH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 51 Compounds of formula I.1d* in which R 4< is C 2 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 52 Compounds of formula I.1d* in which R 4< is CH(CH 3 ) 2 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 53 Compounds of formula I.1d* in which R 4< is SO 2 CH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 54 Compounds of formula I.1d* in which R 4< is C 6 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 55 Compounds of formula I.1d* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 56 Compounds of formula I.1d* in which R 4< is CH 2 OCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 57 Compounds of formula I.1d* in which R 4< is CH 2 C(=O)NHCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 58 Compounds of formula I.1d* in which R 4< is C(=O)OCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 59 Compounds of formula I.1d* in which R 4< is cC 3 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 60 Compounds of formula I.1d* in which R 4< is CH 2 -cC 3 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 61 Compounds of formula I.1d* in which R 4< is CH 2 CF 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 62 Compounds of formula I.1d* in which R 4< is CH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 63 Compounds of formula I.1d* in which R 4< is C 2 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 64 Compounds of formula I.1d* in which R 4< is CH(CH 3 ) 2 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 65 Compounds of formula I.1d* in which R 4< is SO 2 CH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 66 Compounds of formula I.1d* in which R 4< is C 6 H 5 , and R 6< is CH 3 , the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 67 Compounds of formula I.1d* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 68 Compounds of formula I.1d* in which R 4< is CH 2 OCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 69 Compounds of formula I.1d* in which R 4< is CH 2 C(=O)NHCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 70 Compounds of formula I.1d* in which R 4< is C(=O)OCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 71 Compounds of formula I.1d* in which R 4< is cC 3 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 72 Compounds of formula I.1d* in which R 4< is CH 2 -cC 3 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 73 Compounds of formula I.2a* in which R 4< is CH 2 CF 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 74 Compounds of formula I.2a* in which R 4< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 75 Compounds of formula I.2a* in which R 4< is C 2 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 76 Compounds of formula I.2a* in which R 4< is CH(CH 3 ) 2 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 77 Compounds of formula I.2a* in which R 4< is SO 2 CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 78 Compounds of formula I.2a* in which R 4< is C 6 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 79 Compounds of formula I.2a* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 80 Compounds of formula I.2a* in which R 4< is CH 2 OCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 81 Compounds of formula I.2a* in which R 4< is CH 2 C(=O)NHCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 82 Compounds of formula I.2a* in which R 4< is C(=O)OCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 83 Compounds of formula I.2a* in which R 4< is cC 3 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 84 Compounds of formula I.2a* in which R 4< is CH 2 -cC 3 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 85 Compounds of formula I.2b* in which R 4< is CH 2 CF 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 86 Compounds of formula I.2b* in which R 4< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 87 Compounds of formula I.2b* in which R 4< is C 2 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 88 Compounds of formula I.2b* in which R 4< is CH(CH 3 ) 2 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 89 Compounds of formula I.2b* in which R 4< is SO 2 CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 90 Compounds of formula I.2b* in which R 4< is C 6 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 91 Compounds of formula I.2b* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 92 Compounds of formula I.2b* in which R 4< is CH 2 OCH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 93 Compounds of formula I.2b* in which R 4< is CH 2 C(=O)NHCH 3 , and the combination of R', (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 94 Compounds of formula I.2b* in which R 4< is C(=O)OCH 3 , and the combination of R', (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 95 Compounds of formula I.2b* in which R 4< is cC 3 H 5 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 96 Compounds of formula I.2b* in which R 4< is CH 2 -cC 3 H 5 , and the combination of R 1< , (R 3< ) n and R S< for a compound corresponds in each case to one row of Table A Table 97 Compounds of formula I.2c* in which R 4< is CH 2 CF 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 98 Compounds of formula I.2c* in which R 4< is CH 3 , R 6< is Cl, and the combination of R', (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 99 Compounds of formula I.2c* in which R 4< is C 2 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 100 Compounds of formula I.2c* in which R 4< is CH(CH 3 ) 2 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 101 Compounds of formula I.2c* in which R 4< is SO 2 CH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 102 Compounds of formula I.2c* in which R 4< is C 6 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 103 Compounds of formula I.2c* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 104 Compounds of formula I.2c* in which R 4< is CH 2 OCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 105 Compounds of formula I.2c* in which R 4< is CH 2 C(=O)NHCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 106 Compounds of formula I.2c* in which R 4< is C(=O)OCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 107 Compounds of formula I.2c* in which R 4< is cC 3 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 108 Compounds of formula I.2c* in which R 4< is CH 2 -cC 3 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 109 Compounds of formula I.2c* in which R 4< is CH 2 CF 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 110 Compounds of formula I.2c* in which R 4< is CH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 111 Compounds of formula I.2c* in which R 4< is C 2 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 112 Compounds of formula I.2c* in which R 4< is CH(CH 3 ) 2 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 113 Compounds of formula I.2c* in which R 4< is SO 2 CH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 114 Compounds of formula I.2c* in which R 4< is C 6 H 5 , and R 6< is CH 3 , the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 115 Compounds of formula I.2c* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 116 Compounds of formula I.2c* in which R 4< is CH 2 OCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 117 Compounds of formula I.2c* in which R 4< is CH 2 C(=O)NHCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 118 Compounds of formula I.2c* in which R 4< is C(=O)OCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 119 Compounds of formula I.2c* in which R 4< is cC 3 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 120 Compounds of formula I.2c* in which R 4< is CH 2 -cC 3 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 121 Compounds of formula I.2d* in which R 4< is CH 2 CF 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 122 Compounds of formula I.2d* in which R 4< is CH 3 , R 6< is Cl, and the combination of R', (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 123 Compounds of formula I.2d* in which R 4< is C 2 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 124 Compounds of formula I.2d* in which R 4< is CH(CH 3 ) 2 , R 6< is Cl, and the combination of R', (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 125 Compounds of formula I.2d* in which R 4< is SO 2 CH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 126 Compounds of formula I.2d* in which R 4< is C 6 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 127 Compounds of formula I.2d* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 128 Compounds of formula I.2d* in which R 4< is CH 2 OCH 3 , R 6< is Cl, and the combination of R', (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 129 Compounds of formula I.2d* in which R 4< is CH 2 C(=O)NHCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 130 Compounds of formula I.2d* in which R 4< is C(=O)OCH 3 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 131 Compounds of formula I.2d* in which R 4< is cC 3 H 5 , R 6< is Cl, and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 132 Compounds of formula I.2d* in which R 4< is CH 2 -cC 3 H 5 , R 6< is Cl, and the combination of R', (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 133 Compounds of formula I.2d* in which R 4< is CH 2 CF 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 134 Compounds of formula I.2d* in which R 4< is CH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 135 Compounds of formula I.2d* in which R 4< is C 2 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 136 Compounds of formula I.2d* in which R 4< is CH(CH 3 ) 2 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 137 Compounds of formula I.2d* in which R 4< is SO 2 CH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 138 Compounds of formula I.2d* in which R 4< is C 6 H 5 , and R 6< is CH 3 , the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 139 Compounds of formula I.2d* in which R 4< is CH 2 -(4-OCH 3 -C 6 H 4 ), R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 140 Compounds of formula I.2d* in which R 4< is CH 2 OCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 141 Compounds of formula I.2d* in which R 4< is CH 2 C(=O)NHCH 3 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 142 Compounds of formula I.2d* in which R 4< is C(=O)OCH 3 , R 6< is CH 3 , and the combination of R', (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 143 Compounds of formula I.2d* in which R 4< is cC 3 H 5 , R 6< is CH 3 , and the combination of R', (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table 144 Compounds of formula I.2d* in which R 4< is CH 2 -cC 3 H 5 , R 6< is CH 3 , and the combination of R 1< , (R 3< ) n and R 5< for a compound corresponds in each case to one row of Table A Table A No.R 1< (R 3< ) n R 5< A-1H3,5-F 2 HA-2H3,5-Cl 2 HA-3H3,5-Br 2 HA-4H3,5-I 2 HA-5H3,5-(CF 3 ) 2 HA-6H3-Cl,5-FHA-7H3-Cl,5-BrHA-8H3-Cl,5-IHA-9H3-F,5-CNHA-10H3-Cl,5-CNHA-11H3-CF 3 ,5-CNHA-12H3-F,5-CF 3 HA-13H3-Cl,5-CF 3 HA-14H3-Br,5-CF 3 HA-15H3-I,5-CF 3 HA-16H3-Cl,5-SO 2 CH 3 HA-17H3-Cl,5-SO 2 CF 3 HA-18H3-Cl,5-cC 3 H 5 HA-19H3-Cl,5-[2,2-Cl 2 -cC 3 H 3 ]HA-20H3-Cl,5-OCF 3 HA-21H3-Br,5-OCF 3 HA-22H3-F,5-cC 3 H 5 HA-23H3-Cl,5-CH 2 CNHA-24H3-Cl,5-C(CH 3 ) 2 CNHA-25H3-CF 3 ,5-CH 2 CNHA-26H3-CF 3 ,5-C(CH 3 ) 2 CNHA-27H3-CF 3 ,5-SO 2 CH 3 HA-28H3-CF 3 ,5-SO 2 CF 3 HA-29H3-CF 3 ,5-OCF 3 HA-30H3-CF 3 ,5-cC 3 H 5 HA-31H3-Cl,5-[(1-CN)cC 3 H 4 ]HA-32H3-CF 3 ,5-[(1-CN)cC 3 H 4 ]HA-33H3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 ]HA-34H3-OCF 3 ,5-cC 3 H 5 HA-35H3,5-SO 2 CH 3 HA-36H3,5-SO 2 CF 3 HA-37H3-Cl,5-OC 6 H 5 HA-38H3-CF 3 ,5-OC 6 H 5 HA-39H3-CF 3 ,5-[O-(4-Cl-C 6 H 4 )]HA-40CH 2 -cC 3 H 5 3,5-F 2 HA-41CH 2 -cC 3 H 5 3,5-Cl 2 HA-42CH 2 -cC 3 H 5 3,5-Br 2 HA-43CH 2 -cC 3 H 5 3,5-I 2 HA-44CH 2 -cC 3 H 5 3,5-(CF 3 ) 2 HA-45CH 2 -cC 3 H 5 3-Cl,5-FHA-46CH 2 -cC 3 H 5 3-Cl,5-BrHA-47CH 2 -cC 3 H 5 3-Cl,5-IHA-48CH 2 -cC 3 H 5 3-F,5-CNHA-49CH 2 -cC 3 H 5 3-Cl,5-CNHA-50CH 2 -cC 3 H 5 3-CF 3 ,5-CNHA-51CH 2 -cC 3 H 5 3-F,5-CF 3 HA-52CH 2 -cC 3 H 5 3-Cl,5-CF 3 HA-53CH 2 -cC 3 H 5 3-Br,5-CF 3 HA-54CH 2 -cC 3 H 5 3-I,5-CF 3 HA-55CH 2 -cC 3 H 5 3-Cl,5-SO 2 CH 3 HA-56CH 2 -CC 3 H 5 3-Cl,5-SO 2 CF 3 HA-57CH 2 -CC 3 H 5 3-Cl,5-cC 3 H 5 HA-58CH 2 -cC 3 H 5 3-Cl,5-[2,2-Cl 2 -cC 3 H 3 ]HA-59CH 2 -cC 3 H 5 3-Cl ,5-OCF 3 HA-60CH 2 -cC 3 H 5 3-Br,5-OCF 3 HA-61CH 2 -cC 3 H 5 3-F,5-cC 3 H 5 HA-62CH 2 -cC 3 H 5 3-Cl,5-CH 2 CNHA-63CH 2 -cC 3 H 5 3-Cl,5-C(CH 3 ) 2 CNHA-64CH 2 -cC 3 H 5 3-CF 3 ,5-CH 2 CNHA-65CH 2 -cC 3 H 5 3-CF 3 ,5-C(CH 3 ) 2 CNHA-66CH 2 -cC 3 H 5 3-CF 3 ,5-SO 2 CH 3 HA-67CH 2 -cC 3 H 5 3-CF 3 ,5-SO 2 CF 3 HA-68CH 2 -cC 3 H 5 3-CF 3 ,5-OCF 3 HA-69CH 2 -cC 3 H 5 3-CF 3 ,5-cC 3 H 5 HA-70CH 2 -CC 3 H 5 3-Cl,5-[(1-CN)cC 3 H 4 ]HA-71CH 2 -CC 3 H 5 3-CF 3 ,5-[(1-CN)cC 3 H 4 ]HA-72CH 2 -cC 3 H 5 3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 ]HA-73CH 2 -cC 3 H 5 3-OCF 3 ,5-cC 3 H 5 HA-74CH 2 -cC 3 H 5 3,5-SO 2 CH 3 HA-75CH 2 -cC 3 H 5 3,5-SO 2 CF 3 HA-76CH 2 -cC 3 H 5 3-Cl,5-OC 6 H 5 HA-77CH 2 -cC 3 H 5 3-CF 3 ,5-OC 6 H 5 HA-78CH 2 -cC 3 H 5 3-CF 3 ,5-[O-(4-Cl-C 6 H 4 )]HA-79H3,5-F 2 CIA-80H3,5-Cl 2 ClA-81H3,5-Br 2 ClA-82H3,5-I 2 CIA-83H3,5-(CF 3 ) 2 CIA-84H3-Cl,5-FClA-85H3-Cl,5-BrClA-86H3-Cl,5-IClA-87H3-F,5-CNClA-88H3-Cl,5-CNClA-89H3-CF 3 ,5-CNClA-90H3-F,5-CF 3 ClA-91H3-Cl,5-CF 3 ClA-92H3-Br,5-CF 3 ClA-93H3-I,5-CF 3 CIA-94H3-Cl,5-SO 2 CH 3 ClA-95H3-Cl,5-SO 2 CF 3 ClA-96H3-Cl,5-cC 3 H 5 CIA-97H3-Cl,5-[2,2-Cl 2 -cC 3 H 3 ]ClA-98H3-Cl,5-OCF 3 ClA-99H3-Br,5-OCF 3 ClA-100H3-F,5-cC 3 H 5 CIA-101H3-Cl,5-CH 2 CNClA-102H3-Cl,5-C(CH 3 ) 2 CNClA-103H3-CF 3 ,5-CH 2 CNClA-104H3-CF 3 ,5-C(CH 3 ) 2 CNClA-105H3-CF 3 ,5-SO 2 CH 3 ClA-106H3-CF 3 ,5-SO 2 CF 3 ClA-107H3-CF 3 ,5-OCF 3 ClA-108H3-CF 3 ,5-cC 3 H 5 ClA-109H3-Cl,5-[(1-CN)cC 3 H 4 ]ClA-110H3-CF 3 ,5-[(1-CN)cC 3 H 4 ]ClA-111H3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 ]CIA-112H3-OCF 3 ,5-cC 3 H 5 CIA-113H3,5-SO 2 CH 3 ClA-114H3,5-SO 2 CF 3 CIA-115H3-Cl,5-OC 6 H 5 CIA-116H3-CF 3 ,5-OC 6 H 5 CIA-117H3-CF 3 ,5-[O-(4-Cl-C 3 H 4 )]CIA-118CH 2 -cC 3 H 5 3,5-F 2 CIA-119CH 2 -cC 3 H 5 3,5-Cl 2 ClA-120CH 2 -cC 3 H 5 3,5-Br 2 CIA-121CH 2 -cC 3 H 5 3,5-I 2 CIA-122CH 2 -cC 3 H 5 3,5-(CF 3 ) 2 ClA-123CH 2 -cC 3 H 5 3-Cl,5-FCIA-124CH 2 -cC 3 H 5 3-Cl,5-BrClA-125CH 2 -cC 3 H 5 3-Cl,5-IClA-126CH 2 -CC 3 H 5 3-F,5-CNClA-127CH 2 -CC 3 H 5 3-Cl,5-CNClA-128CH 2 -cC 3 H 5 3-CF 3 ,5-CNClA-129CH 2 -cC 3 H 5 3-F,5-CF 3 ClA-130CH 2 -cC 3 H 5 3-Cl,5-CF 3 ClA-131CH 2 -cC 3 H 5 3-Br,5-CF 3 ClA-132CH 2 -cC 3 H 5 3-I,5-CF 3 ClA-133CH 2 -cC 3 H 5 3-Cl,5-SO 2 CH 3 ClA-134CH 2 -cC 3 H 5 3-Cl,5-SO 2 CF 3 ClA-135CH 2 -cC 3 H 5 3-Cl,5-cC 3 H 5 CIA-136CH 2 -cC 3 H 5 3-Cl,5-[2,2-Cl 2 -cC 3 H 3 ]ClA-137CH 2 -cC 3 H 5 3-Cl,5-OCF 3 ClA-138CH 2 -cC 3 H 5 3-Br,5-OCF 3 ClA-139CH 2 -cC 3 H 5 3-F,5-cC 3 H 5 CIA-140CH 2 -CC 3 H 5 3-Cl,5-CH 2 CNClA-141CH 2 -CC 3 H 5 3-Cl,5-C(CH 3 ) 2 CNClA-142CH 2 -cC 3 H 5 3-CF 3 ,5-CH 2 CNClA-143CH 2 -cC 3 H 5 3-CF 3 ,5-C(CH 3 ) 2 CNClA-144CH 2 -cC 3 H 5 3-CF 3 ,5-SO 2 CH 3 ClA-145CH 2 -cC 3 H 5 3-CF 3 ,5-SO 2 CF 3 ClA-146CH 2 -cC 3 H 5 3-CF 3 ,5-OCF 3 ClA-147CH 2 -cC 3 H 5 3-CF 3 ,5-cC 3 H 5 ClA-148CH 2 -cC 3 H 5 3-Cl,5-[(1-CN)cC 3 H 4 ]ClA-149CH 2 -cC 3 H 5 3-CF 3 ,5-[(1-CN)cC 3 H 4 ]ClA-150CH 2 -cC 3 H 5 3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 ]CIA-151CH 2 -cC 3 H 5 3-OCF 3 ,5-CC 3 H 5 CIA-152CH 2 -cC 3 H 5 3,5-SO 2 CH 3 CIA-153CH 2 -cC 3 H 5 3,5-SO 2 CF 3 ClA-154CH 2 -cC 3 H 5 3-Cl,5-OC 6 H 5 ClA-155CH 2 -cC 3 H 5 3-CF 3 ,5-OC 6 H 5 CIA-156CH 2 -cC 3 H 5 3-CF 3 ,5-[O-(4-Cl-C 6 H 4 )]CIA-157H3,5-F 2 CH 3 A-158H3,5-Cl 2 CH 3 A-159H3,5-Br 2 CH 3 A-160H3,5-I 2 CH 3 A-161H3,5-(CF 3 ) 2 CH 3 A-162H3-Cl,5-FCH 3 A-163H3-Cl,5-BrCH 3 A-164H3-Cl,5-ICH 3 A-165H3-F,5-CNCH 3 A-166H3-Cl,5-CNCH 3 A-167H3-CF 3 ,5-CNCH 3 A-168H3-F,5-CF 3 CH 3 A-169H3-Cl,5-CF 3 CH 3 A-170H3-Br,5-CF 3 CH 3 A-171H3-I,5-CF 3 CH 3 A-172H3-Cl,5-SO 2 CH 3 CH 3 A-173H3-Cl,5-SO 2 CF 3 CH 3 A-174H3-Cl,5-cC 3 H 5 CH 3 A-175H3-Cl,5-[2,2-Cl 2 -cC 3 H 3 ]CH 3 A-176H3-Cl,5-OCF 3 CH 3 A-177H3-Br,5-OCF 3 CH 3 A-178H3-F,5-cC 3 H 5 CH 3 A-179H3-Cl,5-CH 2 CNCH 3 A-180H3-Cl,5-C(CH 3 ) 2 CNCH 3 A-181H3-CF 3 ,5-CH 2 CNCH 3 A-182H3-CF 3 ,5-C(CH 3 ) 2 CNCH 3 A-183H3-CF 3 ,5-SO 2 CH 3 CH 3 A-184H3-CF 3 ,5-SO 2 CF 3 CH 3 A-185H3-CF 3 ,5-OCF 3 CH 3 A-186H3-CF 3 ,5-cC 3 H 5 CH 3 A-187H3-Cl,5-[(1-CN)cC 3 H 4 ]CH 3 A-188H3-CF 3 ,5-[(1-CN)cC 3 H 4 ]CH 3 A-189H3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 ]CH 3 A-190H3-OCF 3 ,5-CC 3 H 5 CH 3 A-191H3,5-SO 2 CH 3 CH 3 A-192H3,5-SO 2 CF 3 CH 3 A-193H3-Cl,5-OC 6 H 5 CH 3 A-194H3-CF 3 ,5-OC 6 H 5 CH 3 A-195H3-CF 3 ,5-[O-(4-Cl-C 6 H 4 )]CH 3 A-196CH 2 -CC 3 H 5 3,5-F 2 CH 3 A-197CH 2 -CC 3 H 5 3,5-Cl 2 CH 3 A-198CH 2 -cC 3 H 5 3,5-Br 2 CH 3 A-199CH 2 -cC 3 H 5 3,5-I 2 CH 3 A-200CH 2 -cC 3 H 5 3,5-(CF 3 ) 2 CH 3 A-201CH 2 -cC 3 H 5 3-Cl,5-FCH 3 A-202CH 2 -cC 3 H 5 3-Cl,5-BrCH 3 A-203CH 2 -cC 3 H 5 3-Cl,5-ICH 3 A-204CH 2 -cC 3 H 5 3-F,5-CNCH 3 A-205CH 2 -cC 3 H 5 3-Cl,5-CNCH 3 A-206CH 2 -cC 3 H 5 3-CF 3 ,5-CNCH 3 A-207CH 2 -cC 3 H 5 3-F,5-CF 3 CH 3 A-208CH 2 -cC 3 H 5 3-Cl,5-CF 3 CH 3 A-209CH 2 -cC 3 H 5 3-Br,5-CF 3 CH 3 A-210CH 2 -CC 3 H 5 3-I,5-CF 3 CH 3 A-211CH 2 -CC 3 H 5 3-Cl,5-SO 2 CH 3 CH 3 A-212CH 2 -cC 3 H 5 3-Cl,5-SO 2 CF 3 CH 3 A-213CH 2 -cC 3 H 5 3-Cl,5-cC 3 H 5 CH 3 A-214CH 2 -cC 3 H 5 3-Cl,5-[2,2-Cl 2 -cC 3 H 3 ]CH 3 A-215CH 2 -cC 3 H 5 3-Cl,5-OCF 3 CH 3 A-216CH 2 -cC 3 H 5 3-Br,5-OCF 3 CH 3 A-217CH 2 -cC 3 H 5 3-F,5-cC 3 H 5 CH 3 A-218CH 2 -cC 3 H 5 3-Cl,5-CH 2 CNCH 3 A-219CH 2 -cC 3 H 5 3-Cl,5-C(CH 3 ) 2 CNCH 3 A-220CH 2 -cC 3 H 5 3-CF 3 ,5-CH 2 CNCH 3 A-221CH 2 -cC 3 H 5 3-CF 3 ,5-C(CH 3 ) 2 CNCH 3 A-222CH 2 -cC 3 H 5 3-CF 3 ,5-SO 2 CH 3 CH 3 A-223CH 2 -cC 3 H 5 3-CF 3 ,5-SO 2 CF 3 CH 3 A-224CH 2 -cC 3 H 5 3-CF 3 ,5-OCF 3 CH 3 A-225CH 2 -cC 3 H 5 3-CF 3 ,5-cC 3 H 5 CH 3 A-226CH 2 -cC 3 H 5 3-Cl,5-[(1-CN)cC 3 H 4 ]CH 3 A-227CH 2 -cC 3 H 5 3-CF 3 ,5-[(1-CN)cC 3 H 4 ]CH 3 A-228CH 2 -cC 3 H 5 3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 ]CH 3 A-229CH 2 -cC 3 H 5 3-OCF 3 ,5-cC 3 H 5 CH 3 A-230CH 2 -cC 3 H 5 3,5-SO 2 CH 3 CH 3 A-231CH 2 -CC 3 H 5 3,5-SO 2 CF 3 CH 3 A-232CH 2 -CC 3 H 5 3-Cl,5-OC 6 H 5 CH 3 A-233CH 2 -cC 3 H 5 3-CF 3 ,5-OC 6 H 5 CH 3 A-234CH 2 -cC 3 H 5 3-CF 3 ,5-[O-(4-Cl-C 6 H 4 )]CH 3 A-235H3,5-F 2 OCH 3 A-236H3,5-Cl 2 OCH 3 A-237H3,5-Br 2 OCH 3 A-238H3,5-I 2 OCH 3 A-239H3,5-(CF 3 ) 2 OCH 3 A-240H3-Cl,5-FOCH 3 A-241H3-Cl,5-BrOCH 3 A-242H3-Cl,5-IOCH 3 A-243H3-F,5-CNOCH 3 A-244H3-Cl,5-CNOCH 3 A-245H3-CF 3 ,5-CNOCH 3 A-246H3-F,5-CF 3 OCH 3 A-247H3-Cl,5-CF 3 OCH 3 A-248H3-Br,5-CF 3 OCH 3 A-249H3-I,5-CF 3 OCH 3 A-250H3-Cl,5-SO 2 CH 3 OCH 3 A-251H3-Cl,5-SO 2 CF 3 OCH 3 A-252H3-Cl,5-cC 3 H 5 OCH 3 A-253H3-Cl,5-[2,2-Cl 2 -cC 3 H 3 ]OCH 3 A-254H3-Cl,5-OCF 3 OCH 3 A-255H3-Br,5-OCF 3 OCH 3 A-256H3-F,5-cC 3 H 5 OCH 3 A-257H3-Cl,5-CH 2 CNOCH 3 A-258H3-Cl,5-C(CH 3 ) 2 CNOCH 3 A-259H3-CF 3 ,5-CH 2 CNOCH 3 A-260H3-CF 3 ,5-C(CH 3 ) 2 CNOCH 3 A-261H3-CF 3 ,5-SO 2 CH 3 OCH 3 A-262H3-CF 3 ,5-SO 2 CF 3 OCH 3 A-263H3-CF 3 ,5-OCF 3 OCH 3 A-264H3-CF 3 ,5-cC 3 H 5 OCH 3 A-265H3-Cl,5-[(1-CN)cC 3 H 4 ]OCH 3 A-266H3-CF 3 ,5-[(1-CN)cC 3 H 4 ]OCH 3 A-267H3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 ]OCH 3 A-268H3-OCF 3 ,5-cC 3 H 5 OCH 3 A-269H3,5-SO 2 CH 3 OCH 3 A-270H3,5-SO 2 CF 3 OCH 3 A-271H3-Cl,5-OC 6 H 5 OCH 3 A-272H3-CF 3 ,5-OC 6 H 5 OCH 3 A-273H3-CF 3 ,5-[O-(4-Cl-C 6 H 4 )]OCH 3 A-274CH 2 -cC 3 H 5 3,5-F 2 OCH 3 A-275CH 2 -cC 3 H 5 3,5-Cl 2 OCH 3 A-276CH 2 -cC 3 H 5 3,5-Br 2 OCH 3 A-277CH 2 -cC 3 H 5 3,5-I 2 OCH 3 A-278CH 2 -cC 3 H 5 3,5-(CF 3 ) 2 OCH 3 A-279CH 2 -cC 3 H 5 3-Cl,5-FOCH 3 A-280CH 2 -CC 3 H 5 3-Cl,5-BrOCH 3 A-281CH 2 -CC 3 H 5 3-Cl,5-IOCH 3 A-282CH 2 -cC 3 H 5 3-F,5-CNOCH 3 A-283CH 2 -cC 3 H 5 3-Cl,5-CNOCH 3 A-284CH 2 -cC 3 H 5 3-CF 3 ,5-CNOCH 3 A-285CH 2 -cC 3 H 5 3-F,5-CF 3 OCH 3 A-286CH 2 -cC 3 H 5 3-Cl,5-CF 3 OCH 3 A-287CH 2 -cC 3 H 5 3-Br,5-CF 3 OCH 3 A-288CH 2 -cC 3 H 5 3-I,5-CF 3 OCH 3 A-289CH 2 -cC 3 H 5 3-Cl,5-SO 2 CH 3 OCH 3 A-290CH 2 -cC 3 H 5 3-Cl,5-SO 2 CF 3 OCH 3 A-291CH 2 -cC 3 H 5 3-Cl,5-cC 3 H 5 OCH 3 A-292CH 2 -cC 3 H 5 3-Cl,5-[2,2-Cl 2 -cC 3 H 3 ]OCH 3 A-293CH 2 -cC 3 H 5 3-Cl,5-OCF 3 OCH 3 A-294CH 2 -cC 3 H 5 3-Br,5-OCF 3 OCH 3 A-295CH 2 -cC 3 H 5 3-F,5-cC 3 H 5 OCH 3 A-296CH 2 -cC 3 H 5 3-Cl,5-CH 2 CNOCH 3 A-297CH 2 -cC 3 H 5 3-Cl,5-C(CH 3 ) 2 CNOCH 3 A-298CH 2 -cC 3 H 5 3-CF 3 ,5-CH 2 CNOCH 3 A-299CH 2 -cC 3 H 5 3-CF 3 ,5-C(CH 3 ) 2 CNOCH 3 A-300CH 2 -cC 3 H 5 3-CF 3 ,5-SO 2 CH 3 OCH 3 A-301CH 2 -CC 3 H 5 3-CF 3 ,5-SO 2 CF 3 OCH 3 A-302CH 2 -CC 3 H 5 3-CF 3 ,5-OCF 3 OCH 3 A-303CH 2 -cC 3 H 5 3-CF 3 ,5-cC 3 H 5 OCH 3 A-304CH 2 -cC 3 H 5 3-Cl,5-[(1-CN)cC 3 H 4 ]OCH 3 A-305CH 2 -cC 3 H 5 3-CF 3 ,5-[(1-CN)cC 3 H 4 ]OCH 3 A-306CH 2 -cC 3 H 5 3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 OCH 3 A-307CH 2 -cC 3 H 5 3-OCF 3 ,5-CC 3 H 5 OCH 3 A-308CH 2 -cC 3 H 5 3,5-SO 2 CH 3 OCH 3 A-309CH 2 -cC 3 H 5 3,5-SO 2 CF 3 OCH 3 A-310CH 2 -cC 3 H 5 3-Cl,5-OC 6 H 5 OCH 3 A-311CH 2 -cC 3 H 5 3-CF 3 ,5-OC 6 H 5 OCH 3 A-312CH 2 -cC 3 H 5 3-CF 3 ,5-[O-(4-Cl-C 6 H 4 )]OCH 3 A-313H3,5-F 2 CF 3 A-314H3,5-Cl 2 CF 3 A-315H3,5-Br 2 CF 3 A-316H3,5-I 2 CF 3 A-317H3,5-(CF 3 ) 2 CF 3 A-318H3-Cl,5-FCF 3 A-319H3-Cl,5-BrCF 3 A-320H3-Cl,5-ICF 3 A-321H3-F,5-CNCF 3 A-322H3-Cl,5-CNCF 3 A-323H3-CF 3 ,5-CNCF 3 A-324H3-F,5-CF 3 CF 3 A-325H3-Cl,5-CF 3 CF 3 A-326H3-Br,5-CF 3 CF 3 A-327H3-I,5-CF 3 CF 3 A-328H3-Cl,5-SO 2 CH 3 CF 3 A-329H3-Cl,5-SO 2 CF 3 CF 3 A-330H3-Cl,5-cC 3 H 5 CF 3 A-331H3-Cl,5-[2,2-Cl 2 -cC 3 H 3 CF 3 A-332H3-Cl,5-OCF 3 CF 3 A-333H3-Br,5-OCF 3 CF 3 A-334H3-F,5-cC 3 H 5 CF 3 A-335H3-Cl,5-CH 2 CNCF 3 A-336H3-Cl,5-C(CH 3 ) 2 CNCF 3 A-337H3-CF 3 ,5-CH 2 CNCF 3 A-338H3-CF 3 ,5-C(CH 3 ) 2 CNCF 3 A-339H3-CF 3 ,5-SO 2 CH 3 CF 3 A-340H3-CF 3 ,5-SO 2 CF 3 CF 3 A-341H3-CF 3 ,5-OCF 3 CF 3 A-342H3-CF 3 ,5-cC 3 H 5 CF 3 A-343H3-Cl,5-[(1-CN)cC 3 H 4 ]CF 3 A-344H3-CF 3 ,5-[(1-CN)cC 3 H 4 ]CF 3 A-345H3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 CF 3 A-346H3-OCF 3 ,5-CC 3 H 5 CF 3 A-347H3,5-SO 2 CH 3 CF 3 A-348H3,5-SO 2 CF 3 CF 3 A-349H3-Cl,5-OC 6 H 5 CF 3 A-350H3-CF 3 ,5-OC 3 H 3 CF 3 A-351H3-CF 3 ,5-[O-(4-Cl-C 5 H 4 )]CF 3 A-352CH 2 -cC 3 H 5 3,5-F 2 CF 3 A-353CH 2 -cC 3 H 5 3,5-Cl 2 CF 3 A-354CH 2 -cC 3 H 5 3,5-Br 2 CF 3 A-355CH 2 -cC 3 H 5 3,5-I 2 CF 3 A-356CH 2 -cC 3 H 5 3,5-(CF 3 ) 2 CF 3 A-357CH 2 -cC 3 H 5 3-Cl,5-FCF 3 A-358CH 2 -cC 3 H 5 3-Cl,5-BrCF 3 A-359CH 2 -cC 3 H 5 3-Cl,5-ICF 3 A-360CH 2 -cC 3 H 5 3-F,5-CNCF 3 A-361CH 2 -cC 3 H 5 3-Cl,5-CNCF 3 A-362CH 2 -cC 3 H 5 3-CF 3 ,5-CNCF 3 A-363CH 2 -cC 3 H 5 3-F,5-CF 3 CF 3 A-364CH 2 -cC 3 H 5 3-Cl,5-CF 3 CF 3 A-365CH 2 -cC 3 H 5 3-Br,5-CF 3 CF 3 A-366CH 2 -cC 3 H 5 3-I,5-CF 3 CF 3 A-367CH 2 -cC 3 H 5 3-Cl,5-SO 2 CH 3 CF 3 A-368CH 2 -cC 3 H 5 3-Cl,5-SO 2 CF 3 CF 3 A-369CH 2 -cC 3 H 5 3-Cl,5-cC 3 H 5 CF 3 A-370CH 2 -cC 3 H 5 3-Cl,5-[2,2-Cl 2 -cC 3 H 3 ]CF 3 A-371CH 2 -CC 3 H 5 3-Cl,5-OCF 3 CF 3 A-372CH 2 -CC 3 H 5 3-Br,5-OCF 3 CF 3 A-373CH 2 -cC 3 H 5 3-F,5-cC 3 H 5 CF 3 A-374CH 2 -cC 3 H 5 3-Cl,5-CH 2 CNCF 3 A-375CH 2 -cC 3 H 5 3-Cl,5-C(CH 3 ) 2 CNCF 3 A-376CH 2 -cC 3 H 5 3-CF 3 ,5-CH 2 CNCF 3 A-377CH 2 -CC 3 H 5 3-CF 3 ,5-C(CH 3 ) 2 CNCF 3 A-378CH 2 -cC 3 H 5 3-CF 3 ,5-SO 2 CH 3 CF 3 A-379CH 2 -cC 3 H 5 3-CF 3 ,5-SO 2 CF 3 CF 3 A-380CH 2 -cC 3 H 5 3-CF 3 ,5-OCF 3 CF 3 A-381CH 2 -cC 3 H 5 3-CF 3 ,5-cC 3 H 5 CF 3 A-382CH 2 -cC 3 H 5 3-Cl,5-[(1-CN)cC 3 H 4 ]CF 3 A-383CH 2 -cC 3 H 5 3-CF 3 ,5-[(1-CN)cC 3 H 4 ]CF 3 A-384CH 2 -cC 3 H 5 3-CF 3 ,5-[(2,2-Cl 2 )-cC 3 H 3 CF 3 A-385CH 2 -CC 3 H 5 3-OCF 3 ,5-cC 3 H 5 CF 3 A-386CH 2 -CC 3 H 5 3,5-SO 2 CH 3 CF 3 A-387CH 2 -cC 3 H 5 3,5-SO 2 CF 3 CF 3 A-388CH 2 -cC 3 H 5 3-Cl,5-OC 6 H 5 CF 3 A-389CH 2 -cC 3 H 5 3-CF 3 ,5-OC 6 H 5 CF 3 A-390CH 2 -cC 3 H 5 3-CF 3 ,5-[O-(4-Cl-C B H 4 )]CF 3

[0092] The term "compound(s) of the invention" refers to compound(s) of formula I, or "compound(s) I", and includes their salts, tautomers, stereoisomers, and N-oxides.

[0093] The invention also relates to agrochemical compositions comprising an auxiliary and at least one compound I.

[0094] An agrochemical composition comprises a pesticidally effective amount of a compound I.

[0095] An agrochemical composition comprises a pesticidally effective amount of a compound I.

[0096] The compounds I can be converted into customary types of agro-chemical compositions, e.g. solutions, emulsions, suspensions, dusts, powders, pastes, granules, pressings, capsules, and mixtures thereof. Examples for composition types are suspensions (e.g. SC, OD, FS), emulsifiable concentrates (e.g. EC), emulsions (e.g. EW, EO, ES, ME), capsules (e.g. CS, ZC), pastes, pastilles, wettable powders or dusts (e.g. WP, SP, WS, DP, DS), pressings (e.g. BR, TB, DT), granules (e.g. WG, SG, GR, FG, GG, MG), insecticidal articles (e.g. LN), as well as gel formulations for the treatment of plant propagation materials e.g. seeds (e.g. GF). These and further compositions types are defined in the "Catalogue of pesticide formulation types and international coding system", Technical Monograph No. 2, 6th Ed. May 2008, CropLife International. Suitable auxiliaries are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetters, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion agents, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, anti-freezing agents, anti-foaming agents, colorants, tackifiers and binders. Suitable solvents and liquid carriers are water and organic solvents. Suitable solid carriers or fillers are mineral earths.

[0097] Suitable surfactants are surface-active compounds, e.g. anionic, cationic, nonionic, and amphoteric surfactants, block polymers, polyelectrolytes. Such surfactants can be used as emulsifier, dispersant, solubilizer, wetter, penetration enhancer, protective colloid, or adjuvant. Surfactants are listed in McCutcheon's, Vol. 1: Emulsifiers & Detergents, McCutcheon's Directories, Glen Rock, USA, 2008 (International or North American Ed.). Suitable anionic surfactants are alkali, alkaline earth, or ammonium salts of sulfonates, sulfates, phosphates, carboxylates. Suitable nonionic surfactants are alkoxylates, N-subsituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants. Suitable cationic surfactants are quaternary surfactants.

[0098] The agrochemical compositions generally comprise between 0.01 and 95%, preferably between 0.1 and 90%, and most preferably between 0.5 and 75%, by weight of active substance. The active substances are employed in a purity of from 90% to 100%, preferably from 95% to 100%.

[0099] Various types of oils, wetters, adjuvants, or fertilizer may be added to the active substances or the compositions comprising them as premix or, if appropriate not until immediately prior to use (tank mix). These agents can be admixed with the compositions according to the invention in a weight ratio of 1:100 to 100:1.

[0100] The user applies the composition according to the invention usually from a predosage device, a knapsack sprayer, a spray tank, a spray plane, or an irrigation system. Usually, the agrochemical composition is made up with water, buffer, and / or further auxiliaries to the desired application concentration and the ready-to-use spray liquor or the agrochemical composition according to the invention is thus obtained. Usually, 20 to 2000 liters of the ready-to-use spray liquor are applied per hectare of agricultural useful area.

[0101] The compounds I are suitable for use in protecting crops, plants, plant propagation materials, e.g. seeds, or soil or water, in which the plants are growing, from attack or infestation by animal pests. Therefore, the invention also relates to a plant protection method, which comprises contacting crops, plants, plant propagation materials, e.g. seeds, or soil or water, in which the plants are growing, to be protected from attack or infestation by animal pests, with a pesticidally effective amount of a compound I.

[0102] The compounds I are also suitable for use in combating or controlling animal pests. Therefore, the invention also relates to a method of combating or controlling animal pests, which comprises contacting the animal pests, their habitat, breeding ground, or food supply, or the crops, plants, plant propagation materials, e.g. seeds, or soil. or the area, material or environment in which the animal pests are growing or may grow, with a pesticidally effective amount of a compound I. The compounds I are effective through both contact and ingestion to any and all developmental stages, such as egg, larva, pupa, and adult.

[0103] The compounds I can be applied as such or in form of compositions comprising them.

[0104] The application can be carried out both before and after the infestation of the crops, plants, plant propagation materials by the pests.

[0105] The term "contacting" includes both direct contact (applying the compounds / compositions directly on the animal pest or plant) and indirect contact (applying the compounds / compositions to the locus).

[0106] The term "animal pest" includes arthropods, gastropods, and nematodes. Preferred animal pests according to the invention are arthropods, preferably insects and arachnids, in particular insects.

[0107] The term "plant" includes cereals, e.g. durum and other wheat, rye, barley, triticale, oats, rice, or maize (fodder maize and sugar maize / sweet and field corn); beet, e.g. sugar beet, or fodder beet; fruits, e.g. pomes, stone fruits, or soft fruits, e.g. apples, pears, plums, peaches, nectarines, almonds, cherries, papayas, strawberries, raspberries, blackberries or gooseberries; leguminous plants, e.g. beans, lentils, peas, alfalfa. or soybeans; oil plants, e.g. rapeseed (oilseed rape), turnip rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts, or soybeans; cucurbits, e.g. squashes, pumpkins, cucumber or melons; fiber plants, e.g. cotton, flax, hemp, or jute; citrus fruit, e.g. oranges, lemons, grapefruits or mandarins; vegetables, e.g. eggplant, spinach, lettuce (e.g. iceberg lettuce), chicory, cabbage, asparagus, cabbages, carrots, onions, garlic, leeks, tomatoes, potatoes, cucurbits or sweet peppers; lauraceous plants, e.g. avocados, cinnamon, or camphor; energy and raw material plants, e.g. corn, soybean, rapeseed, sugar cane or oil palm; tobacco; nuts, e.g. walnuts; pistachios; coffee; tea; bananas; vines; hop; sweet leaf (Stevia); natural rubber plants or ornamental and forestry plants, shrubs, broad-leaved trees or evergreens, eucalyptus; turf; lawn; grass. Preferred plants include potatoes, sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton, soybeans, rapeseed, legumes, sunflowers, coffee, or sugar cane; fruits; vines; ornamentals; or vegetables, e.g. cucumbers, tomatoes, beans or squashes.

[0108] The term "seed" embraces seeds and plant propagules including true seeds, seed pieces, suckers, corms, bulbs, fruit, tubers, grains, cuttings, cut shoots, and means preferably true seeds.

[0109] "Pesticidally effective amount" means the amount of active ingredient needed to achieve an observable effect on growth, including the effects of necrosis, death, retardation, prevention, and removal, destruction, or otherwise diminishing the occurrence and activity of the target organism. The pesticidally effective amount can vary for the various compounds / compositions used in the invention. A pesticidally effective amount of the compositions will also vary according to the prevailing conditions e.g. desired pesticidal effect and duration, weather, target species, locus, mode of application.

[0110] For use in treating crop plants, e.g. by foliar application, the rate of application of the active ingredients of this invention may be in the range of 0.0001 g to 4000 g per hectare, e.g. from 1 g to 2 kg per hectare or from 1 g to 750 g per hectare, desirably from 1 g to 100 g per hectare.

[0111] The compounds I are also suitable for use against non-crop insect pests. For use against said non-crop pests, compounds I can be used as bait composition, gel, general insect spray, aerosol, as ultra-low volume application and bed net (impregnated or surface applied).

[0112] The term "non-crop insect pest" refers to pests, which are particularly relevant for non-crop targets, e.g. ants, termites, wasps, flies, ticks, mosquitoes, bed bugs, crickets, or cockroaches, such as: Aedes aegypti, Musca domestica, Tribolium spp.; termites such as Reticulitermes flavipes, Coptotermes formosanus; roaches such as Blatella germanica, Periplaneta Americana; ants such as Solenopsis invicta, Linepithema humile, and Camponotus pennsylvanicus.

[0113] The bait can be a liquid, a solid or a semisolid preparation (e.g. a gel). For use in bait compositions, the typical content of active ingredient is from 0.001 wt% to 15 wt%, desirably from 0.001 wt% to 5 wt% of active compound.

[0114] The compounds I and its compositions can be used for protecting wooden materials such as trees, board fences, sleepers, frames, artistic artifacts, etc. and buildings, but also construction materials, furniture, leathers, fibers, vinyl articles, electric wires and cables etc. from ants, termites and / or wood or textile destroying beetles, and for controlling ants and termites from doing harm to crops or human beings (e.g. when the pests invade into houses and public facilities or nest in yards, orchards or parks).

[0115] Customary application rates in the protection of materials are, e.g., from 0.001 g to 2000 g or from 0.01 g to 1000 g of active compound per m 2< treated material, desirably from 0.1 g to 50 g per m 2< .

[0116] Insecticidal compositions for use in the impregnation of materials typically contain from 0.001 to 95 wt%, preferably from 0.1 to 45 wt%, and more preferably from 1 to 25 wt% of at least one repellent and / or insecticide.

[0117] The compounds of the invention are especially suitable for efficiently combating animal pests e.g. arthropods, and nematodes including: insects from the sub-order of Auchenorrhyncha, e.g. Amrasca biguttula, Empoasca spp., Ne-photettix virescens, Sogatella furcifera, Mahanarva spp., Laodelphax striatellus, Nilaparvata lugens, Diaphorina citri; Lepidoptera, e.g. Helicoverpa spp., Heliothis virescens, Lobesia botrana, Ostrinia nubilalis, Plu-tella xylostella, Pseudoplusia includens, Scirpophaga incertulas, Spodoptera spp., Trichop-lusia ni, Tuta absoluta, Cnaphalocrocis medialis, Cydia pomonella, Chilo suppressalis, Anticar-sia gemmatalis, Agrotis ipsilon, Chrysodeixis includens; True bugs, e.g. Lygus spp., Stink bugs such as Euschistus spp., Halyomorpha halys, Nezara viridula, Piezodorus guildinii, Dichelops furcatus; Thrips, e.g. Frankliniella spp., Thrips spp., Dichromothrips corbettii; Aphids, e.g. Acyrthosiphon pisum, Aphis spp., Myzus persicae, Rhopalosiphum spp., Schi-zaphis graminum, Megoura viciae; Whiteflies, e.g. Trialeurodes vaporariorum, Bemisia spp.; Coleoptera, e.g. Phyllotreta spp., Melanotus spp., Meligethes aeneus, Leptinotarsa decimline-ata, Ceutorhynchus spp., Diabrotica spp., Anthonomus grandis, Atomaria linearia, Agriotes spp., Epilachna spp.; Flies, e.g. Delia spp., Ceratitis capitate, Bactrocera spp., Linomyza spp.; Mosquitoes (Diptera), e.g. Aedes aegypti, A. albopictus, A. vexans, Anastrepha ludens, Anopheles maculipennis, A. crucians, A. albimanus, A. gambiae, A. freeborni, A. leucosphyrus, A. minimus, A. quadrimaculatus; Coccoidea, e.g. Aonidiella aurantia, Ferrisia virgate; Anthropods of class Arachnida (Mites), e.g. Penthaleus major, Tetranychus spp.; Nematodes, e.g. Heterodera glycines, Meloidogyne sp., Pratylenchus spp., Caenorhabditis el-egans.

[0118] The compounds I are suitable for use in treating or protecting animals against infestation or infection by parasites. Therefore, the invention also relates to the use of a compound of the invention for the manufacture of a medicament for the treatment or protection of animals against infestation or infection by parasites. Furthermore, the invention relates to a method of treating or protecting animals against infestation and infection by parasites, which comprises orally, topically or parenterally administering or applying to the animals a parasiticidally effective amount of a compound I.

[0119] The invention also relates to the non-therapeutic use of compounds of the invention for treating or protecting animals against infestation and infection by parasites. Moreover, the invention relates to a non-therapeutic method of treating or protecting animals against infestation and infection by parasites, which comprises applying to a locus a parasiticidally effective amount of a compound I.

[0120] The compounds of the invention are further suitable for use in combating or controlling parasites in and on animals. Furthermore, the invention relates to a method of combating or controlling parasites in and on animals, which comprises contacting the parasites with a parasitically effective amount of a compound I.

[0121] The invention also relates to the non-therapeutic use of compounds I for controlling or combating parasites. Moreover, the invention relates to a non-therapeutic method of combating or controlling parasites, which comprises applying to a locus a parasiticidally effective amount of a compound I.

[0122] The compounds I can be effective through both contact (via soil, glass, wall, bed net, carpet, blankets, or animal parts) and ingestion (e.g. baits). Furthermore, the compounds I can be applied to any and all developmental stages.

[0123] The compounds I can be applied as such or in form of compositions comprising them.

[0124] The term "locus" means the habitat, food supply, breeding ground, area, material or environment in which a parasite is growing or may grow outside of the animal.

[0125] As used herein, the term "parasites" includes endo- and ectoparasites. In some embodiments of the invention, endoparasites can be preferred. In other embodiments, ectoparasites can be preferred. Infestations in warm-blooded animals and fish include lice, biting lice, ticks, nasal bots, keds, biting flies, muscoid flies, flies, myiasitic fly larvae, chiggers, gnats, mosquitoes and fleas.

[0126] The compounds of the invention are especially useful for combating the following parasites: Cimex lectularius, Rhipicephalus sanguineus, and Ctenocephalides felis.

[0127] As used herein, the term "animal" includes warm-blooded animals (including humans) and fish. Preferred are mammals, such as cattle, sheep. swine, camels, deer, horses, pigs, poultry, rabbits, goats, dogs and cats, water buffalo, donkeys, fallow deer and reindeer, and also in furbear-ing animals such as mink, chinchilla and raccoon, birds such as hens, geese, turkeys and ducks and fish such as fresh- and salt-water fish such as trout, carp and eels. Particularly preferred are domestic animals, such as dogs or cats.

[0128] The compounds I may be applied in total amounts of 0.5 mg / kg to 100 mg / kg per day, preferably 1 mg / kg to 50 mg / kg per day.

[0129] For oral administration to warm-blooded animals, the compounds I may be formulated as animal feeds, animal feed premixes, animal feed concentrates, pills, solutions, pastes, suspensions, drenches, gels, tablets, boluses and capsules. For oral administration, the dosage form chosen should provide the animal with 0.01 mg / kg to 100 mg / kg of animal body weight per day of the compounds I, preferably with 0.5 mg / kg to 100 mg / kg of animal body weight per day.

[0130] Alternatively, the compounds I may be administered to animals parenterally, e.g., by intrarumi-nal, intramuscular, intravenous or subcutaneous injection. The compounds I may be dispersed or dissolved in a physiologically acceptable carrier for subcutaneous injection. Alternatively, the compounds I may be formulated into an implant for subcutaneous administration. In addition, the compounds I may be transdermally administered to animals. For parenteral administration, the dosage form chosen should provide the animal with 0.01 mg / kg to 100 mg / kg of animal body weight per day of the compounds I.

[0131] The compounds I may also be applied topically to the animals in the form of dips, dusts, powders, collars, medallions, sprays, shampoos, spot-on and pour-on formulations and in ointments or oil-in-water or water-in-oil emulsions. For topical application, dips and sprays usually contain 0.5 ppm to 5,000 ppm and preferably 1 ppm to 3,000 ppm of the compounds I. In addition, the compounds I may be formulated as ear tags for animals, particularly quadrupeds e.g. cattle and sheep.

[0132] Oral solutions are administered directly.

[0133] Solutions for use on the skin are trickled on, spread on, rubbed in, sprinkled on or sprayed on. Gels are applied to or spread on the skin or introduced into body cavities.

[0134] Pour-on formulations are poured or sprayed onto limited areas of the skin, the active compound penetrating the skin and acting systemically. Pour-on formulations are prepared by dissolving, suspending, or emulsifying the active compound in suitable skin-compatible solvents or solvent mixtures.

[0135] Emulsions can be administered orally, dermally or as injections.

[0136] Suspensions can be administered orally or topically / dermally.

[0137] Semi-solid preparations can be administered orally or topically / dermally.

[0138] For the production of solid preparations, the active compound is mixed with suitable excipients, if appropriate with addition of auxiliaries, and brought into the desired form.

[0139] The compositions which can be used in the invention can comprise generally from about 0.001 to 95% of the compound I.

[0140] Ready-to-use preparations contain the compounds acting against parasites, preferably ectoparasites, in concentrations of 10 ppm to 80% by weight, preferably from 0.1 to 65% by weight, more preferably from 1 to 50% by weight, most preferably from 5 to 40% by weight. Preparations which are diluted before use contain the compounds acting against ectoparasites in concentrations of 0.5 to 90% by weight, preferably of 1 to 50% by weight.

[0141] Furthermore, the preparations comprise the compounds of formula I against endoparasites in concentrations of 10 ppm to 2% by weight, preferably of 0.05 to 0.9% by weight, very particularly preferably of 0.005 to 0.25% by weight.

[0142] Solid formulations which release compounds of the invention may be applied in total amounts of 10 mg / kg to 300 mg / kg, preferably 20 mg / kg to 200 mg / kg, most preferably 25 mg / kg to 160 mg / kg body weight of the treated animal in the course of three weeks.A. Preparation examples

[0143] The compounds were characterized by melting point determination, by NMR spectroscopy or by the mass-to-charge ratio ([m / z]) and retention time (RT; [min.]), as determined by mass spectrometry (MS) coupled with HPLC analysis (HPLC-MS = high performance liquid chromatography-coupled mass spectrometry) or LC analysis (LC-MS = liquid chromatography-coupled mass spectrometry).

[0144] Method A: HPLC: Shimadzu Nexera UHPLC + Shimadzu LCMS-2020, ESI; Column: Phenom-enex Kinetex 1.7µm XB-C18 100A, 2.1x50mm: Mobile phase: A: water + 0.1% TFA; B: ACN; Temperature: 60°C; Gradient: 5% B to 100% B in 1.5 min; 100% B 0.25 min; Flow: 0.8 mL / min to 1.0 mL / min in 1.51 min; MS: ESI positive; Mass range (m / z): 100-700.

[0145] Method B: LC: Shimadzu LC-30AD, ESI; Column: Kinetex EVO C18.5µm 2.1x30mm; Mobile phase: A: water + 0.04% TFA; B: ACN + 0.02% TFA; Temperature: 40°C; Gradient: 5% B to 100% B in 2.5 min; 100% B to 5% B in 0.02min; 5% B for 0.5min; Flow: 0.8mL / min; MS: ESI positive; Mass range: 100-2000.

[0146] Method C: HPLC / MS: Agilent 1200 HPLC MSD:1956A single quadrupole MSD, ES-API; Column: Luna C18 2.0x50mm 5µm; Mobile phase: A: 0.04% TFA in water; B: 0.02% TFA in ACN; Temperature: 40°C; Gradient: 5% B for 0.4min; 5% B to 95% B in 2.6 min; 95% B for 1 min; 95% B to 5% B in 0.01 min; 5% B for 0.5min; Flow: 1.0mL / min; MS: ES-API positive; Mass range: 50-1500.

[0147] Method D: HPLC / MS: Agilent 1200 HPLC MSD:6120 single quadrupole MSD; Column: XBridge C18 2.1x50mm 5µm; Mobile phase: A: 10nM NH4HCO3 in water; B: ACN; Temperature: 40°C; Gradient: 5% B to 95% B in 3.4 min; 95% B for 0.45 min; 95% B to 5% B in 0.01min; 5% B for 0.64 min; Flow: 0.8 mL / min; MS: ES-API positive; Mass range: 50-2000.Example 1: preparation of 3-bromo-N-[1-[3-(4-methyl-5-oxo-1,2,4-triazol-1-yl)pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (I-1)Step 1: Preparation of 2-[(3-chloropyrazin-2-yl)hydrazono]acetic acid

[0148] To a solution of (3-chloropyrazin-2-yl)hydrazine (5 g, 0.0346 mol) in aq. HCl (6N, 10mL) was added glyoxylic acid (3.18g, 0.0346mol) at 20°C. The mixture was stirred at 80°C for 12h, during which time a yellow precipitate was formed. Completion was determined by LCMS. The mixture was filtered and the filter cake was dried to furnish 2-[(3-chloropyrazin-2-yl)hydrazono]acetic acid (6.2g, 89% yield) as a yellow solid.

[0149] 1< H-NMR (400MHz, DMSO-ds) δ = 8.02 (s, 1H), 8.22 (d, J=2.5Hz, 1H), 8.51 (d, J=2.5Hz, 1H), 11.35-11.83 (m, 1H).Step 2: preparation of 2-(3-chloropyrazin-2-yl)-4H-1,2,4-triazol-3-one

[0150] To a suspension of 2-[(3-chloropyrazin-2-yl)hydrazono]acetic acid (3 g, 0.0149mol) in THF (50mL) were added trimethylsilyl azide (2.24g, 0.0194mol), propanephosphonic acid anhydride (T3P, 6.19g, 0.0194mol), and diisopropylethylamine (5.79g, 0.0449mol) at 20°C. The mixture was stirred at 80°C for 12h, at which time completion was determined by LCMS. The volatiles were removed under reduced pressure and the residue was purified by preparative HPLC (NH 4 HCO 3 ) to deliver 2-(3-chloropyrazin-2-yl)-4H-1,2,4-triazol-3-one (740mg, 25% yield) as a yellow solid.

[0151] 1< H-NMR (400 MHz, CDCl 3 ) δ = 7.72 (s, 1H), 8.52 (d, J=2.3Hz, 1H), 8.55-8.59 (m, 1H).Step 3: Preparation of 2-(3-chloropyrazin-2-yl)-4-methyl-1,2,4-triazol-3-one

[0152] To a solution of 2-(3-chloropyrazin-2-yl)-4H-1,2,4-triazol-3-one (1.3g, 0.0067mol) in acetonitrile (100 mL) were added CH 3 I (1.87g, 0.0132mol) and K 2 CO 3 (1.7g, 0.0132mol) at 20°C. The mixture was stirred at 25°C for 48h, at which time completion was determined by TLC (EtOAc). The reaction mixture was quenched with H 2 O (100mL) and extracted with EtOAc (3x30mL). The combined organic layers were washed with brine (20mL), dried over Na 2 SO 4 , and concentrated. The residue was purified by chromatographic column on silica gel (eluent PE: EtOAc = 100:0 to 10:90) to furnish 2-(3-chloropyrazin-2-yl)-4-methyl-1,2,4-triazol-3-one (0.47 g, 34% yield) as a yellow solid.

[0153] 1< H-NMR (400MHz, CDCl 3 ) δ = 3.41 (s, 3H), 7.65 (s, 1H), 8.48 (d, J=2.4Hz, 1H), 8.53 (d, J=2.4Hz, 1H).Step 4: preparation of 2-[3-(1-ethoxyvinyl)pyrazin-2-yl]-4-methyl-1,2,4-triazol-3-one

[0154] To a mixture of 2-(3-chloropyrazin-2-yl)-4-methyl-1,2,4-triazol-3-one (0.47g, 0.00222mol) in toluene (50mL) were added tributyl(1-ethoxyvinyl)stannane (0.802g, 0.00222mol) and Pd(PPh 3 ) 2 Cl 2 (156mg) at 25°C. The mixture was stirred for 12h at 100°C, at which time completion was determined by LCMS. After cooling the reaction mixture to 25°C, aq. sat. KF (30mL) was added and stirred for 30min. The mixture was filtered through a celite pad, and the filtrate was extracted with EtOAc (3x30mL). The combined organic layers were washed with brine (10mL), dried over Na 2 SO 4 , and concentrated. The residue was purified by chromatographic column on silica gel (PE: EtOAc = 100:0 to 5:95) to deliver 2-[3-(1-ethoxyvinyl)pyrazin-2-yl]-4-methyl-1,2,4-triazol-3-one (0.25g, 46% yield) as an yellow oil, which was employed in the next step without further purification.Step 5: preparation of 2-(3-acetylpyrazin-2-yl)-4-methyl-1,2,4-triazol-3-one

[0155] To a solution of 2-[3-(1-ethoxyvinyl)pyrazin-2-yl]-4-methyl-1,2,4-triazol-3-one (0.25g, 0.001mol) in THF (3mL) was added aq. HCl (2M, 3mL) dropwise at 25°C. The resulting mixture was stirred for 16h at 25°C, at which time completion was determined by LCMS. The reaction mixture was diluted with H 2 O (50mL) and extracted with EtOAc (3x20mL). The combined organic layers were washed with brine (40mL), dried over Na 2 SO 4 , and concentrated to furnish 2-(3-acetylpyrazin-2-yl)-4-methyl-1,2,4-triazol-3-one (0.18 g, crude) as a yellow oil.

[0156] 1< H-NMR (400MHz, CDCl 3 ) δ = 2.79 (s, 3H), 3.36 (s, 3H), 7.66 (s, 1H), 8.57 (d, J=2.4Hz, 1H), 8.66 (d, J=2.4Hz, 1H).Step 6: preparation of 2-[3-(1-aminoethyl)pyrazin-2-yl]-4-methyl-1,2,4-triazol-3-one

[0157] To a solution of 2-(3-acetylpyrazin-2-yl)-4-methyl-1,2,4-triazol-3-one (0.15g, 0.684mmol) in MeOH (5mL) were added NH 4 OAc (0.527g, .6.84mmol), NaBH 3 CN (86mg, 0.136mmol), and NH 3 (7N in MeOH, 2mL) at 20°C. The resulting mixture was stirred for 16h at 20°C, at which time completion was determined by TLC (DCM:MeOH =10:1). The volatiles were removed under reduced pressure and H 2 O (50mL) was added. The pH of the resulting solution was adjusted to 10 by addition of aq. NaOH, and the mixture was extracted with DCM / iPrOH (3 / 1, 3x20mL). The combined organic layers were dried over Na 2 SO 4 and concentrated to deliver 2-[3-(1-aminoethyl)pyrazin-2-yl]-4-methyl-1,2,4-triazol-3-one (50 mg, crude) as a yellow oil, which was employed in the next step without further purification.Step 7: preparation of 3-bromo-N-[1-[3-(4-methyl-5-oxo-1,2,4-triazol-1-yl)pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (I-1)

[0158] To a solution of 3-bromo-5-(trifluoromethyl)benzoic acid (0.489g, 0.00182mol) in acetonitrile (10mL) were added N'-tetramethylformamidinium hexafluorophosphate (0.765g, 0.00273mol), N-methylimidazole (0.448g, 0.0055mol), and 2-[3-(1-aminoethyl)pyrazin-2-yl]-4-methyl-1,2,4-triazol-3-one (0.4g, 0.00182mol) at 20°C. The mixture was stirred at 20°C for 0.5h, at which time completion was determined by LCMS. The reaction mixture was quenched with H 2 O (10mL) and extracted with EtOAc (3x30mL). The combined organic layers were washed with brine (10mL), dried over Na 2 SO 4 , and concentrated. The residue was purified by preparative HPLC (NH 4 HCO 3 ) to deliver 3-bromo-N-[1-[3-(4-methyl-5-oxo-1,2,4-triazol-1-yl)pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (I-1, 0.2g, 23% yield) as a pink solid.

[0159] 1< H-NMR (400MHz, CDCl 3 ) δ = 1.62 (d, J=6.6Hz, 3H), 3.44 (s, 3H), 5.65-5.80 (m, 1H), 7.40 (br d, J=7.4Hz, 1H), 7.67 (s, 1H), 7.89 (s, 1H), 7.98 (s, 1H), 8.11 (s, 1H), 8.59 (d, J=2.0Hz, 1H), 8.67 (d, J=2.0Hz, 1H).

[0160] LCMS: calculated mass: 471; observed mass: 471.473.Example 2: preparation of 3-bromo-N-[1-[3-[5-oxo-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-1-yl]py-razin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (I-2)Step 1: Preparation of 2-(3-chloropyrazin-2-yl)-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one

[0161] To a solution of 2-(3-chloropyrazin-2-yl)-4H-1,2,4-triazol-3-one (1.2g, 0.0061mol) in acetonitrile (100mL) were added 2,2,2-trifluoroethyl trifluoromethanesulfonate (1.4g, 0.0061mol) and K 2 CO 3 (1.57g, 0.0122mol) at 20°C. The resulting mixture was stirred at 25°C for 12h, at which time the product was the major component of the mixture, as determined by LCMS. The reaction mixture was quenched with H 2 O (50mL) and extracted with EtOAc (3x20mL). The combined organic layers were washed with brine (40mL), dried over Na 2 SO 4 , and concentrated. The residue was purified by chromatographic column on silica gel (PE: EtOAc = 100:0 to 35:75) to furnish 2-(3-chlo-ropyrazin-2-yl)-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one (1.2g, 71% yield) as a white solid.

[0162] 1< H-NMR (400MHz, CDCl 3 ) δ = 4.37 (q, J=8.5Hz, 2H), 7.78 (s, 1H), 8.52 (d, J=2.4Hz, 1H), 8.56 (d, J=2.4Hz, 1H).Step 2: Preparation of 2-[3-(1-ethoxyvinyl)pyrazin-2-yl]-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one

[0163] To a solution of 2-(3-chloropyrazin-2-yl)-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one (0.2g, 0.715mmol) in toluene (10mL) were added tributyl(1-ethoxyvinyl)stannane (0.258g, 0.715mmol) and Pd(PPh 3 ) 2 Cl 2 (50mg) at 25°C. The resulting mixture was stirred for at 100°C for 12h, at which time completion was determined by LCMS, then cooled to 25°C. The mixture was diluted with aq. sat. KF (20mL), stirred for 30min, and filtered through a celite pad. The filtrate was extracted with EtOAc (3x30mL) and the combined organic layers were washed with brine (10mL), dried over Na 2 SO 4 , and concentrated. The residue was purified by chromatographic column on silica gel (PE: EtOAc = 100:0 to 65:35) to deliver 2-[3-(1-ethoxyvinyl)pyrazin-2-yl]-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one (0.1 g, 44% yield) as a yellow oil, which was employed in the next step without further purification.Step 3: Preparation of 2-(3-acetylpyrazin-2-yl)-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one

[0164] To a solution of 2-[3-(1-ethoxyvinyl)pyrazin-2-yl]-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one (0.1g, 0.317mmol) in THF (3mL) was added aq. HCl (2M, 3mL) dropwise at 0°C. The resulting mixture was stirred for 16h at 25°C, at which time completion was determined by LCMS. The reaction mixture was quenched with H 2 O (5mL) and extracted with EtOAc (3x20mL). The combined organic layers were washed with brine (4mL), dried over Na 2 SO 4 , and concentrated. The residue was purified by preparative TLC (EtOAc) to furnish 2-(3-acetylpyrazin-2-yl)-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one (50mg, 50% yield) as a yellow solid.

[0165] 1< H-NMR (400MHz, CDCl 3 ) δ = 2.78 (s, 3H), 4.31 (q, J=8.5Hz, 2H), 7.78 (s, 1H), 8.63 (d, J=2.4Hz, 1H), 8.69 (d, J=2.4Hz, 1H).Step 4: Preparation of 2-[3-(1-aminoethyl)pyrazin-2-yl]-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one

[0166] To a solution of 2-(3-acetylpyrazin-2-yl)-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one (0.4g, 1.39mmol) in MeOH (50mL) were added NH 4 OAc (1.07g, 13.9mmol), NaBH 3 CN (175mg, 2.79mmol) and NH 3 (7N in MeOH, 2mL) at 20°C, and the resulting mixture was stirred at 40°C for 16h, at which time completion was determined by TLC (DCM:MeOH =10:1)(aq. NH 3 ). The volatiles were removed under reduced pressure and the residue was taken in H 2 O (5mL). The pH was adjusted to 10 by addition of aq. NaOH, and the resulting solution was extracted with DCM / iPrOH (3 / 1, 3x20mL). The combined organic layers were dried over Na 2 SO 4 and concentrated to deliver 2-[3-(1-aminoethyl)pyrazin-2-yl]-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one (50mg, crude) as a yellow oil, which was employed in the next step without further purification.Step 5: Preparation of 3-bromo-N-[1-[3-[5-oxo-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-1-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (I-2)

[0167] To a solution of 3-bromo-5-(trifluoromethyl)benzoic acid (0.448g, 0.00156mol) in acetonitrile (10mL) were added N'-tetramethylformamidinium hexafluorophosphate (0.438g, 0.00156mol), N-methylimidazole (0.256g, 0.0031mol) and 2-[3-(1-aminoethyl)pyrazin-2-yl]-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-one (0.3g, 0.00104mol) at 20°C, and the resulting mixture was stirred for 0.5h at which time completion was determined by LCMS. The reaction mixture was quenched with H 2 O (10mL) and extracted with EtOAc (3x30mL). The combined organic layers were washed with brine (10mL), dried over Na 2 SO 4 , and concentrated. The residue was purified by preparative HPLC (NH 4 HCO 3 ) to deliver 3-bromo-N-[1-[3-[5-oxo-4-(2,2,2-trifluoroethyl)-1,2,4-triazol-1-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (I-2, 0.2g, 36% yield) as a pink solid. 1< H-NMR (400MHz, CDCl 3 ) δ = 1.63 (d, J=6.6Hz, 3H), 4.31-4.48 (m, 2H), 5.70 (dq, J=6.6Hz, J=7.6Hz, 1H), 7.32 (br d, J=7.6Hz, 1H), 7.81 (s, 1H), 7.90 (s, 1H), 7.97 (s, 1H), 8.10 (s, 1H), 8.61 (d, J=2.4Hz, 1H), 8.70 (d, J=2.4Hz, 1H).

[0168] LCMS: calculated mass: 539; observed mass: 539.541.Example 3: Preparation of 3-bromo-N-[1-[3-[4-[(4-methoxyphenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]pyrazin-2-yl]ethyl]-5-methylsulfonyl-benzamide (I-3)Step 1: preparation of 2-(3-acetylpyrazin-2-yl)-4-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-one

[0169] To a solution of 1-(3-chloropyrazin-2-yl)ethanone (4.56g, 29.2mmol) in DMF (100mL) were added 4-[(4-methoxyphenyl)methyl]-1H-1,2,4-triazol-5-one (9g, 43.9mmol) and K 2 CO 3 (6g, 43.9mmol) at 20°C and the resulting mixture was stirred at 80°C for 12h, at which time completion was determined by TLC (PE:EtOAc=3:1). The reaction mixture was poured intoH 2 O (50mL) and extracted with EtOAc (200mLx3). The combined organic layers were washed with brine (50mLx2), dried over Na 2 SO 4 , filtered, concentrated and purified by silicagel column (EtOAc in PE=0% to 100%) to deliver 2-(3-acetylpyrazin-2-yl)-4-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-one (5g, 53% yield) as a yellow solid.

[0170] 1< H-NMR (400MHz, CDCl 3 ): δ = 8.65 (d, J=2.38Hz, 1H), 8.57 (d, J=2.38Hz, 1H), 7.52 (s, 1H), 7.25 (s, 2H), 6.90-6.94 (m, 2H), 4.77 (s, 2H), 3.82 (s, 3H), 2.81 (s, 3H).Step 2: preparation of 2-[3-(1-aminoethyl)pyrazin-2-yl]-4-[(4-methoxyphenyl)methyl]-1,2,4-tria-zol-3-one

[0171] To a solution of 2-(3-acetylpyrazin-2-yl)-4-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-one (5g, 15.38mmol) in MeOH (250mL) were added NH 4 OAc (11.85g, 153.8mmol), NH 3 / MeOH (7N, 150mL) at 25°C and the resulting mixture was stirred for 1h. Subsequently, NaBH 3 CN (2.9g, 46.15mmol) was added portionwise at 0°C and the mixture was stirred at 50°C for 12h, at which time completion was determined by LCMS. The reaction mixture was quenched withH 2 O (10mL), concentrated and extracted with EtOAc (50mLx3), the organic layer was dried over Na 2 SO 4 and concentrated to deliver 2-[3-(1-aminoethyl)pyrazin-2-yl]-4-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-one (5g) as brown oil. The crude product was employed in the next step without further purification.

[0172] 1< H-NMR (400MHz, DMSO-d 6 ) δ = 8.72-8.82 (m, 1H), 8.55 (d, J=1.50Hz, 1H), 8.31-8.39 (m, 1H), 7.32 (d, J=8.50Hz, 2H), 6.96 (br d, J=8.13Hz, 2H), 4.82 (s, 2H), 4.04 (q, J=6.17Hz, 1H), 3.75 (s, 3H), 1.20-1.36 (m, 3H).Step 3: preparation of 3-bromo-N-[1-[3-[4-[(4-methoxyphenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]pyrazin-2-yl]ethyl]-5-methylsulfonyl-benzamide

[0173] To a solution of 3-bromo-5-methylsulfonyl-benzoic acid (1.14g, 4.1mmol) in DMF (40mL) were added 2-[3-(1-aminoethyl)pyrazin-2-yl]-4-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-one (2g, 6.14mmol), HATU (2.32g, 6.14mmol), and triethylamine (1.03g, 10.24mmol) at 20°C. The mixture was stirred for 12h, at which time completion was determined by TLC (PE:EtOAc=1:1). The mixture was poured into H 2 O (100mL), extracted with EtOAc (50mLx3), washed with brine (50mL), dried over Na 2 SO 4 , filtered, and concentrated. The residue was purified by column chromatography (EtOAc in PE = 0%~100%) and subsequently triturated with MTBE (10mL) to furnish 3-bromo-N-[1-[3-[4-[(4-methoxyphenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]pyrazin-2-yl]ethyl]-5-methylsulfonyl-benzamide (1-3, 200mg, 17% yield) as light pink solid.

[0174] 1< H-NMR (400MHz, CDCl 3 ) δ = 8.52-8.77 (m, 2H), 8.24 (d, J=1.63Hz, 2H), 8.18-8.22 (m, 1H), 7.51-7.57 (m, 1H), 7.48 (br d, J=7.75Hz, 1H), 7.30-7.36 (m, 2H), 6.91-6.98 (m, 2H), 5.76 (dq, J=6.94Hz, 1H), 4.85 (s, 2H), 3.84 (s, 3H), 3.10 (s, 3H), 1.61 (d, J=6.63Hz, 3H).Example 4: Preparation of 3-bromo-N-[1-[3-[4-(cyclopropylmethyl)-5-oxo-1,2,4-triazol-1-yl]py-razin-2-yl]ethyl]-5-methylsulfonyl-benzamide (I-5)Step 1: preparation of 3-bromo-5-methylsulfonyl-N-[1-[3-(5-oxo-4H-1,2,4-triazol-1-yl)pyrazin-2-yl]ethyl]benzamide (INT)

[0175] To a solution of 3-bromo-N-[1-[3-[4-[(4-methoxyphenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]pyrazin-2-yl]ethyl]-5-methylsulfonyl-benzamide (I-3, 900mg, 2.70mmol) in MeCN / H 2 O (1:1 v / v, 9mL) was added ceric ammonium nitrate (3.36g, 6.14mmol). The reaction mixture was stirred at 50°C for 16h, at which time completion was determined by TLC (EtOAc). The mixture was poured into H 2 O (20mL) and extracted with EtOAc (20mLx3). The combined organic layers were washed with brine (20mL), dried over Na 2 SO 4 , filtered, and concentrated. The residue was purified by trituration with MTBE (10mL) followed by preparative HPLC (neutral, CH 3 CN / H 2 O) to deliver 3-bromo-5-methylsulfonyl-N-[1-[3-(5-oxo-4H-1,2,4-triazol-1-yl)pyrazin-2-yl]ethyl]benzamide (INT, 150mg, 20% yield) as a yellow solid.

[0176] 1< H-NMR (400MHz, DMSO-d 6 ): δ = 11.91 (br d, J=2.50Hz, 1H), 9.21 (d, J=7.50Hz, 1H), 8.77 (d, J=2.38Hz, 1H), 8.62 (d, J=2.38Hz, 1H), 8.28-8.36 (m, 2H), 8.18-8.25 (m, 1H), 8.11 (s, 1H), 5.48 (dq, J=6.88, 7.50Hz, 1H), 3.31 (br s, 3H), 1.56 (d, J=6.88Hz, 3H).

[0177] LCMS: Method B, RT=1.14 min; m / z [M+H] +< calc. 467.0, found 467.0 / 469.0 (Br isotopes).Step 2: preparation of 3-bromo-N-[1-[3-[4-(cyclopropylmethyl)-5-oxo-1,2,4-triazol-1-yl]pyrazin-2-yl]ethyl]-5-methylsulfonyl-benzamide (I-5)

[0178] To a solution of 3-bromo-5-methylsulfonyl-N-[1-[3-(5-oxo-4H-1,2,4-triazol-1-yl)pyrazin-2-yl]ethyl]benzamide (INT, 230mg, 0.494mmol) in DMF (8mL) were added Cs 2 CO 3 (482mg, 1.48mmol) and bromomethylcyclopropane (100mg, 0.74mmol) at 15°C. The resulting mixture was stirred at 50°C for 16h, at which time completion was determined by LCMS. The mixture was poured into H 2 O (15mL) and extracted with EtOAc (50mLx3). The organic layers were washed with brine (15mLx3), dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by preparative HPLC (TFA, MeCN / H 2 O) to deliver 3-bromo-N-[1-[3-[4-(cyclopropylmethyl)-5-oxo-1,2,4-triazol-1-yl]pyrazin-2-yl]ethyl]-5-methylsulfonyl-benzamide (I-5, 150mg, 58% yield) as a white solid.

[0179] 1< H-NMR (400MHz, CDCl 3 ) δ = 8.66 (d, J=2.38Hz, 1H), 8.60 (d, J=2.38Hz, 1H), 8.25 (d, J=1.76Hz, 2H), 8.20-8.22 (m, 1H), 7.84 (s, 1H), 7.49-7.54 (m, 1H), 5.72-5.80 (m, 1H), 3.62 (d, J=7.28Hz, 2H), 3.11 (s, 3H), 1.62 (d, J=6.78Hz, 3H), 1.22-1.27 (m, 1H), 0.71-0.77 (m, 2H), 0.43-0.48 (m, 2H).Example 5: Preparation of 3-bromo-N-methyl-N-[1-[3-(4-methyl-5-oxo-1,2,4-triazol-1-yl)pyra-zin-2-yl]ethyl]-5-methylsulfonyl-benzamide (I-8)

[0180] To a solution of 3-bromo-5-methylsulfonyl-N-[1-[3-(5-oxo-4H-1,2,4-triazol-1-yl)pyrazin-2-yl]ethyl]benzamide (INT, 220mg, 0.471mmol) in DMF (10mL) was added NaH (28mg, 1.177mmol) at 0°C. The mixture was stirred at 0°C for 30min. CH 3 I (201mg, 1.413mmol) was added. The mixture was stirred at 15°C for 6h, at which time completion was determined by LCMS. The reaction mixture was poured into H 2 O (30mL) and extracted with EtOAc (20mLx3). The organic layers were washed with brine (20mLx3), dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by preparative HPLC (TFA, MeCN / H 2 O) to furnish 3-bromo-N-methyl-N-[1-[3-(4-methyl-5-oxo-1,2,4-triazol-1-yl)pyrazin-2-yl]ethyl]-5-methylsulfonylbenzamide (I-8, 78mg, 33% yield) as a yellow syrup.

[0181] 1< H-NMR (400MHz, DMSO-d 6 ) δ = 8.87 (d, J=2.26Hz, 1H), 8.74 (d, J=2.26Hz, 1H), 8.23 (s, 1H), 8.15 (s, 1H), 7.87 (s, 1H), 7.85 (s, 1H), 6.09 (q, J=6.57Hz, 1H), 3.32 (s, 3H), 3.23 (s, 3H), 2.51-2.52 (m, 3H), 1.58 (d, J=6.78Hz, 3H).

[0182] With appropriate modification of the starting materials, the procedures given in the synthesis descriptions were used to obtain further compounds I. The compounds obtained in this manner are listed in the table that follows, together with physical data. Table I - Compounds of formula I with R 2< = CH 3 No.R 1< X(R 3< ) n R 4< R 5< Q 1< Q 2< Qphys. dataMethodHPLC RT [min]M+H [m / z]I-1HCH3-Br, 5-CF 3 CH 3 HNCHCHB1.410473.0I-2HCH3-Br, 5-CF 3 CH 2 CF 3 HNCHCHA1.139539.3I-3HCH3-Br, 5-SO 2 CH 3 CH 2 -(4-OCH 3 -C 6 H 4 )HNCHCHB1.394589.1I-4HCH3-Br, 5-CF 3 CH 2 CF 3 HCHCHCHB1.563540.0I-5HCH3-Br, 5-SO 2 CH 3 CH 2 cC 3 H 5 HNCHCHB1.306523.1I-6CH 2 -(2,2-F 2 -cC 3 H 3 )CH3-Br, 5-SO 2 CH 3 C 2 H 5 HNCHCHB1.369587.2I-7HCH3-Cl, 5-CF 3 C 5 H 5 HNCHCHB1.548489.2I-8CH 3 CH3-Br, 5-SO 2 CH 3 CH 3 HNCHCHC1.999497.0I-9HCH3-Cl, 5-CF 3 SO 2 CH 3 HNCHCHB1.474491.2I-10HCH3,5-(CF 3 ) 2 CH 3 HNCHCHB1.409461.2I-11HCH3,5-(CF 3 ) 2 CH 2 CF 3 HNCHCHB1.542529.2I-12HN3,5-Cl 2 C 2 H 5 HNCHCHB1.257408.2I-13HCH3-Br, 5-CF 3 CH 2 CF 3 HCHNCHB1.665541.2I-14HCH3-Cl, 5-SO 2 CH 3 CH 2 CF 3 HCHCBrCHB1.573584.1I-15CH 2 -cC 3 H 5 CH3,5-(CF 3 ) 2 CH 2 CF 3 HNCHCHB1.651583.3I-16HCH3-CI, 5-CF 3 CH 2 CF 3 HCHCBrCHB1.857574.1I-17HCH3-Br, 5-SO 2 CH 3 cC 3 H 5 HNCHCHC2.067509.0I-18HCH3-Br, 5-SO 2 CH 3 CH 3 NCHCHB1.394560.2I-19HCH3-Br, 5-OCF 3 CH 2 cC 3 H 5 HNCHCHD2.842527.1I-20HCH3,5-(CF 3 ) 2 CH 2 CHC=Cl 2 HNCHCHD3.043555.1I-21HCH3,5-(CF 3 ) 2 CH 2 C(O)N(CH 3 )C 2 H 5 HNCHCHD2.607546.2I-22HCH3-Br, 5-CNCH 2 cC 3 H 5 HNCHCHD2.428470.1I-23HCH3-Cl, 5-CF 3 cC 3 H 5 HNCHCHB1.542453.2I-24HCH3-Br, 5-SO 2 CH 3 CH 2 cC 3 H 5 CH 3 NCHCHB1.400537.2I-25HCH3-CI, 5-CF 3 CH 2 CF 3 HCHCClCHB1.836528.2I-26HCH3-[SO 2 (4-F-CeH 4 )], 5-CIcC 3 H 5 HNCHCHB1.539543.2I-27HCH3-Br, 5-CNC 2 H 5 HNCHCHD2.226444.1I-28HCH3-Br, 5-OCF 3 C 2 H 5 HNCHCHD2.674501.1I-29HCH3,5-(CF 3 ) 2 CH 2 -(2,2-Cl-cC 3 H 3 )HNCHCHC2.834569.0I-30HCH3-CI, 5-CF 3 CH 2 CF 3 HCHCCNCHB1.741519.2I-31HCH3-CI, 5-CF 3 CH 2 CF 3 HCHCHCClB1.823528.1I-32HCH3-CF 3 , 5-CNCH 2 CF 3 HCHCCNCHB1.627510.2I-33HCH3-CF 3 , 5-CNCH 2 CF 3 HCHCHCCNB1.660510.2I-34HCH3-CI, 5-CF 3 CH 2 CF 3 HCHCHCCNB1.770519.2I-35HCH3-CI, 5-CF 3 CH 2 CF 3 HCHCHNB1.613495.1I-36HCH3-Br, 5-CIC 2 H 5 CINCHCHB1.667487.0I-37CH 2 -cC 3 H 5 CH3,5-(CF 3 ) 2 CH 3 NCHCHA1.105592.1I-38CH 2 -cC 3 H 5 CH3,5-(CF 3 ) 2 C 5 H 5 HNCHCHA1.328577.3I-39CH 2 -cC 3 H 5 CH3,5-(CF 3 ) 2 CH 3 NCHCHA1.297597.3& denotes the bond to the remainder of the molecule II. Evaluation of pesticidal activity:

[0183] The activity of the compounds of formula I can be demonstrated and evaluated by the following biological tests.B.1 Diamond back moth (Plutella xylostella)

[0184] The active compound was dissolved at the desired concentration in a mixture of 1:1 (vol:vol) distilled water : acetone. Surfactant (Kinetic HV) was added at a rate of 0.01% (vol / vol). The test solution was prepared on the day of use.

[0185] Leaves of cabbage were dipped in test solution and air-dried. Treated leaves were placed in petri dishes lined with moist filter paper and inoculated with ten 3rd instar larvae. Mortality was recorded 72 hours after treatment. Feeding damages were also recorded using a scale of 0-100%.

[0186] In this test, compoundsl-1, I-2, I-4, I-5, 1-7, I-9, I-10, I-11, I-12, I-13, I-15, and I-16, resp., at 300 ppm showed at least 75% mortality in comparison with untreated controls.B.2 Green Peach Aphid (Myzus persicae)

[0187] For evaluating control of green peach aphid (Myzus persicae) through systemic means the test unit consisted of 96-well-microtiter plates containing liquid artificial diet under an artificial mem brane.

[0188] The compounds were formulated using a solution containing 75% v / v water and 25% v / v DMSO. Different concentrations of formulated compounds were pipetted into the aphid diet, using a custom built pipetter, at two replications.

[0189] After application, 5-8 adult aphids were placed on the artificial membrane inside the microtiter plate wells. The aphids were then allowed to suck on the treated aphid diet and incubated at about 23 ± 1°C and about 50 ± 5 % relative humidity for 3 days. Aphid mortality and fecundity was then visually assessed.

[0190] In this test, compoundsl-1, I-2, I-3, I-4, 1-5, I-6, I-7, I-8, I-9, I-10, I-11, I-12, I-13, I-14, I-15, I-17, I-18, I-23, I-24, I-26, I-30, I-31, and I-32, resp., at 2500 ppm showed at least 75% mortality in comparison with untreated controls.B.3 Tobacco budworm (Heliothis virescens)

[0191] For evaluating control of tobacco budworm (Heliothis virescens) the test unit consisted of 96-well-microtiter plates containing an insect diet and 15-25 H. virescens eggs.

[0192] The compounds were formulated using a solution containing 75% v / v water and 25% v / v DMSO. Different concentrations of formulated compounds were sprayed onto the insect diet at 10 µl, using a custom-built micro atomizer, at two replications.

[0193] After application, microtiter plates were incubated at about 28 ± 1°C and about 80 ± 5 % relative humidity for 5 days. Egg and larval mortality was then visually assessed.

[0194] In this test, compoundsl-1, 1-2, 1-4, 1-7, 1-10, I-11, I-13, I-15, I-16, 1-23, I-25, I-26, I-31, I-33, and I-38, resp., at 2500 ppm showed at least 75% mortality in comparison with untreated controls.B.4 Boll weevil (Anthonomus grandis)

[0195] For evaluating control of boll weevil (Anthonomus grandis) the test unit consisted of 96-well-microtiter plates containing an insect diet and 5-10 A. grandis eggs.

[0196] The compounds were formulated using a solution containing 75% v / v water and 25% v / v DMSO. Different concentrations of formulated compounds were sprayed onto the insect diet at 5 µl, using a custom-built micro atomizer, at two replications.

[0197] After application, microtiter plates were incubated at about 25 ± 1°C and about 75 ± 5 % relative humidity for 5 days. Egg and larval mortality was then visually assessed.

[0198] In this test, compoundsl-1, I-2, I-4, 1-5, I-6, I-7, I-9, I-10, I-11, I-12, I-13, I-14, I-15, 1-16, I-17, I-23, 1-24, I-25, I-26, I-30, I-31, 1-32, I-33, I-35, and I-38, resp., at 2500 ppm showed at least 75% mortality in comparison with untreated controls.B.5. Southern armyworm (Spodoptera eridania), 2nd instar larvae

[0199] The active compounds were formulated by a Tecan liquid handler in 100% cyclohexanone as a 10,000 ppm solution supplied in tubes. The 10,000 ppm solution was serially diluted in 100% cyclohexanone to make interim solutions. These served as stock solutions for which final dilutions were made by the Tecan in 50% acetone:50% water (v / v) into 10 or 20ml glass vials. A nonionic surfactant (Kinetic ®< ) was included in the solution at a volume of 0.01% (v / v). The vials were then inserted into an automated electrostatic sprayer equipped with an atomizing nozzle for application to plants / insects. Lima bean plants (variety Sieva) were grown 2 plants to a pot and selected for treatment at the 1st true leaf stage. Test solutions were sprayed onto the foliage by an automated electrostatic plant sprayer equipped with an atomizing spray nozzle. The plants were dried in the sprayer fume hood and then removed from the sprayer. Each pot was placed into perforated plastic bags with a zip closure. Ten to 11 armyworm larvae were placed into the bag and the bags zipped closed. Test plants were maintained in a growth room at about 25°C and about 20-40% relative humidity for 4 days, avoiding direct exposure to fluorescent light (14:10 light:dark photoperiod) to prevent trapping of heat inside the bags. Mortality and reduced feeding were assessed 4 days after treatment, compared to untreated control plants.

[0200] In this test, compoundsl-1, I-2, I-4, I-5, I-7, I-10, I-11, I-12, I-15, I-16, I-19, I-20, I-21, I-22, I-23, I-25, and I-26, resp., at 300 ppm showed at least 75 % mortality in comparison with untreated controls.B.6 Orchid thrips (Dichromothrips corbettl)

[0201] Dichromothrips corbetti adults used for bioassay were obtained from a colony maintained continuously under laboratory conditions. For testing purposes, the test compound is diluted in a 1:1 mixture of acetone:water (vol:vol), plus Kinetic HV at a rate of 0.01% v / v.

[0202] Thrips potency of each compound was evaluated by using a floral-immersion technique. All petals of individual, intact orchid flowers were dipped into treatment solution and allowed to dry in Petri dishes. Treated petals were placed into individual re-sealable plastic along with about 20 adult thrips. All test arenas were held under continuous light and a temperature of about 28°C for duration of the assay. After 3 days, the numbers of live thrips were counted on each petal. The percent mortality was recorded 72 hours after treatment.

[0203] In this test, compounds I-1, I-2, I-9, I-10, I-15, and I-17, resp., at 300 ppm showed at least 75% mortality in comparison with untreated controls.

[0204] The beneficial activity of the triazolone compounds according to the invention over structurally close compounds known from prior art with N-bonded triazoles was demonstrated by the following comparative experiments:B.7 Yellow fever mosquito (Aedes aegypti)

[0205] For evaluating control of yellow fever mosquito (Aedes aegypti) the test unit consisted of 96-well-microtiter plates containing 200µl of tap water per well and 5-15 freshly hatched A. aegypti larvae.

[0206] The active compounds were formulated using a solution containing 75% (v / v) water and 25% (v / v) DMSO. Different concentrations of formulated compounds or mixtures were sprayed onto the insect diet at 2.5µl, using a custom-built micro atomizer, at two replications.

[0207] After application, microtiter plates were incubated at 28 ± 1°C, 80 ± 5 % RH for 2 days. Larval mortality was then visually assessed. StructureExampleB.2, 10 ppmB.6, 100 ppm I-10100100 WO2021 / 037614 P46250StructureExampleB.2, 25 ppmB.7, 10 ppm I-15100100 WO2021 / 037614 P48500

Claims

1. Compounds of formula I wherein R1 is H, OH, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C5-alkoxy, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-alkyl-C3-C6-cycloalkyl, C1-C4-alkyl-C3-C6-halocycloalkyl, which groups are unsubstituted, or partially or fully substituted with R11; or C(=N-R11)R12, C(O)R11a; R11 is CN, NO2, NR12R13, C(O)NH2, C(S)NH2, C(O)OH, OR14, Si(CH3)3; C1-C6-alkyl; C1-C6-haloalkyl; C2-C6-alkenyl; C2-C6-haloalkenyl; C2-C6-alkynyl; C2-C6-haloalkynyl; C3-C4-cycloalkyl-C1-C2-alkyl, which ring is unsubstituted or substi-tuted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with halogen, C1-C3-haloalkyl, and / or CN; R11a is NR12R13, C(O)NH2, C(S)NH2, C(O)OH, OR14, Si(CH3)3; C1-C6-haloalkyl; C2-C6-alkenyl; C2-C6-haloalkenyl; C2-C6-alkynyl; C2-C6-haloalkynyl; C3-C6-cycloalkyl-C1-C2-alkyl, which ring is unsubstituted or substituted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with halogen, C1-C3-haloalkyl, and / or CN; R12, R13 are independently from each other H, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-haloalkyl, C3-C6-cycloalkyl, C(O)-C1-C4-alkyl, C(O)-C1-C4-haloalkyl, C(O)-C3-C4-cycloalkyl, C(O)-C3-C4-halocycloalkyl, C(O)NR121R131, S(O)m-C1-C4-haloalkyl, S(O)m-C3-C6-cycloalkyl, S(O)m-C3-C6-halocycloalkyl; 3-to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with halogen, C1-C3-haloalkyl, and / or CN; R121 and R131 are independently from each other H, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy; C1-C4-alkyl-phenyl, C1-C4-alkyl-3-6-membered hetaryl, phenyl, 3- to 6-membered heterocyclyl or 5- or 6-membered hetaryl, which rings are unsubstituted or substituted with halogen, C1-C3-haloalkyl, and / or CN; or R121 and R131 together with the nitrogen atom they are bound to form a 3-6 membered saturated, partially or fully unsaturated heterocycle, which may further contain 1 or 2 heteroatoms ring members selected from N, O and S, wherein S may be oxidized, which heterocycle is unsubstituted or substituted with halogen, C1-C3-haloalkyl, and / or CN; or R12 and R13 together with the nitrogen atom they are bound to form a 3-6 membered saturated, partially unsaturated, or aromatic heterocycle, which may contain 1 or 2 additional heteroatoms selected from N, O and S, wherein S may be partially or fully oxidized, and which is unsubstituted or substituted with oxo, and / or R3; or R12 and R13 together with the nitrogen atom they are bound to form a group N=S(=O)R14aR14b, wherein R14a and R14b are defined as R14; m is 0, 1, or 2; R14 is H, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C3-C4-cycloalkyl-C1-C2-alkyl, C3-C4-halocycloalkyl-C1-C2-alkyl, C(O)-C1-C4-alkyl, C(O)-C1-C4-haloalkyl, C(O)-C3-C4-cycloalkyl, C(O)-C3-C4-halocycloalkyl, or phenyl which is unsubstituted or partially or fully substituted with R3; R2 is CH3; X is CH, CR3, or N; R3 is halogen, CN, NO2, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C3-C6-halocyclo-alkyl, OR14, S(O)m-R14; which are unsubstituted or substituted with R3a; and wherein R3 is in positions 3 and 5; R3a halogen, CN, NO2, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy-C1-C4-alkyl, OR15, C1-C4-haloalkoxy, C3-C4-cycloalkyl, C3-C4-halocycloalkyl, S(O)m-C1-C4-alkyl, S(O)m-C1-C4-haloalkyl, S(O)m-C3-C4-cycloalkyl, S(O)m-C3-C4-halocycloalkyl; n is 2; R4 is C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C3-C6-halocycloalkyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, each unsubstituted or partially or fully substituted with R41; S(O)m-C1-C4-alkyl, S(O)m-C1-C4-haloalkyl, S(O)m-C3-C6-cyclo¬alkyl, S(O)m-C3-C6-hal-ocycloalkyl, NR12R13, C(O)NR12R13, C(O)OR14, 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R3; R41 is H, OR15, NR12R13, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C(O)-C1-C4-alkyl, C(O)-C1-C4-haloalkyl, C(O)-C3-C4-cycloalkyl, C(O)-C3-C4-halocycloal-kyl, C(O)OR15, C(O)NR121R131; S(O)m-C1-C4-haloalkyl, S(O)m-C3-C4-cycloalkyl, S(O)m-C3-C4-halocycloalkyl; 3-to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl; which cyclic R41 groups are unsubstituted or partially or fully substituted with halogen, C1-C3-haloalkyl, and / or CN; R15 is H, C1-C4-alkyl, or C1-C4-haloalkyl, C3-C6-cycloalkyl, C1-C6-halocycloalkyl, which carbon chains are unsubstituted or partially or fully substituted with R11; or 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R3; R5 is H, halogen, CN, OR15, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C3-C6-cycloalkyl, C1-C4-alkyl-phenyl, C1-C4-alkyl-3-6-membered hetaryl, phenyl, 3- to 6-membered heterocyclyl or 5- or 6-membered hetaryl, which rings are unsubstituted or substituted with halogen, C1-C3-haloalkyl, and / or CN; Q, Q1, and Q2 are, independently from each other, N or CR6, wherein no more than one of Q, Q1, and Q2 is N; R6 is H, halogen, CN, OR14, NR12R13, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C(O)NR12R13, C(O)OR14, S(O)m-C1-C4-alkyl, S(O)m-C1-C4-haloalkyl, S(O)m-C3-C6-cycloalkyl, S(O)m-C3-C6-halocycloalkyl; and the N-oxides, stereoisomers and agriculturally or veterinarily acceptable salts thereof.

2. Compounds of formula I according to claim 1, wherein R12, R13 are independently from each other H, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloal-koxy, C1-C4-haloalkyl, C3-C6-cycloalkyl, C(O)-C1-C4-alkyl, C(O)-C1-C4-haloalkyl, C(O)-C3-C4-cycloalkyl, C(O)-C3-C4-halocycloalkyl, C(O)NR121R131, S(O)m-C1-C4-haloalkyl, S(O)m-C3-C6-cycloalkyl, S(O)m-C3-C6-halocycloalkyl; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with halogen, C1-C3-haloalkyl, and / or CN; R121 and R131 are independently from each other H, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy; C1-C4-alkyl-phenyl, C1-C4-alkyl-3-6-membered hetaryl, phenyl, 3- to 6-membered heterocyclyl or 5- or 6-membered hetaryl, which rings are unsubstituted or substituted with halogen, C1-C3-haloalkyl, and / or CN; or R121 and R131 together with the nitrogen atom they are bound to form a 3-6 membered saturated, partially or fully unsaturated heterocycle, which may further contain 1 or 2 heteroatoms ring members selected from N, O and S, wherein S may be oxidized, which heterocycle is unsubstituted or substituted with halogen, C1-C3-haloalkyl, and / or CN; or R12 and R13 together with the nitrogen atom they are bound to form a 3-6 membered saturated, partially unsaturated, or aromatic heterocycle, which may contain 1 or 2 additional heteroatoms selected from N, O and S, wherein S may be partially or fully oxidized, and which is unsubstituted or substituted with R3; or R12 and R13 together with the nitrogen atom they are bound to form a group N=S(=O)R14aR14b, wherein R14a and R14b are defined as R14; R3 is halogen, CN, NO2, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C1-C6-halocyclo-alkyl, OR14, S(O)m-R14; wherein rings are unsubstituted or substituted with R3a; R3a halogen, CN, NO2, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-haloalkoxy, C3-C4-cycloalkyl, C3-C4-halocycloalkyl, S(O)m-C1-C4-alkyl, S(O)m-C1-C4-haloalkyl, S(O)m-C3-C4-cycloalkyl, S(O)m-C3-C4-halocycloalkyl; n is 2; R41 is H, OR15, NR12R13, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C(O)-C1-C4-alkyl, C(O)-C1-C4-haloalkyl, C(O)-C3-C4-cycloalkyl, C(O)-C3-C4-halocycloalkyl, C(O)NR121R131; S(O)m-C1-C4-haloalkyl, S(O)m-C3-C3-cycloalkyl, S(O)m-C3-C4-halocycloalkyl; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl; which cyclic R41 groups are unsubstituted or partially or fully substituted with halogen, C1-C3-haloalkyl, and / or CN; Q1 and Q2 are, independently from each other, N or CR6; R6 is H, halogen, CN, OR14, NR12R13, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C(O)NR12R13, C(O)OR14, S(O)m-C1-C4-alkyl, S(O)m-C1-C4-haloalkyl, S(O)m-C3-C6-cycloalkyl, S(O)m-C3-C6-halocycloalkyl; Q1 and Q2 are, independently from each other, N or CR6, and Q is CH.

3. Compounds of formula I according to claim 1 or 2, wherein R1 is H.

4. Compounds of formula I according to any of claim 1 to 3, wherein R3 is halogen, CN, C1-C4-haloalkyl, C1-C4-haloalkoxy, C3-C4-cycloalkyl unsubstituted or substituted with one or more CN, C3-C4-halocycloalkyl, S(O)m-C1-C4-alkyl, S(O)m-C1-C4-haloalkyl, S(O)m-C3-C4-cycloalkyl, S(O)m-C3-C4-halocycloalkyl, or S(O)m-R14, wherein R14 is phenyl, which is partially substituted with R3a.

5. Compounds of formula I according to any one of claims 1 to 4, wherein X is CH.

6. Compounds of formula I according to any one of claims 1 to 5, wherein R4 is C1-C3-alkyl, C3-C6-cycloalkyl, C1-C3-haloalkyl, C1-C4-alkoxy-C1-C4-alkyl, CH2C(O)NH-C1-C6-alkyl, S(O)m-C1-C4-alkyl, or phenyl unsubstituted or substituted with one or more groups R3 as defined in claim 4.

7. Compounds of formula I according to any one of the preceding claims, which correspond to formula I.a 8. Compounds of formula I according to any one of the preceding claims, which correspond to formula I.b, wherein R6 is preferably selected from H, halogen, and C1-C4-alkyl.

9. Compounds of formula I according to claim 8, wherein R6 is selected from H, halogen, and C1-C4-alkyl.

10. Compounds of formula I according to any one of the preceding claims, which consist mainly of the isomer I.A.

11. Intermediate compounds of formula INT wherein the variables are as defined for formula I in any one of the preceding claims.

12. An agricultural or veterinary composition comprising at least one compound according to any one of claims 1 to 10 and / or at least one agriculturally or veterinarily acceptable salt thereof, and at least one inert liquid and / or solid agriculturally or veterinarily acceptable carrier.

13. An agricultural composition for combating animal pests comprising at least one compound as defined in any of claims 1 to 10 and at least one inert liquid and / or solid acceptable carrier and, if desired, at least one surfactant.

14. A compound as defined in any one of claims 1 to 10 for use in combating or controlling invertebrate pests.

15. A method for protecting growing plants from attack or infestation by invertebrate pests, which method comprises contacting a plant, or soil or water in which the plant is growing, with a pesticidally effective amount of at least one compound as defined in any of claims 1 to 10.

16. Seed comprising a compound as defined in any of claims 1 to 10, or the enantiomers, diastereomers or salts thereof, in an amount of from 0.1 g to 10 kg per 100 kg of seed.

17. A compound of the formula I as defined in any of claims 1 to 10, a stereoisomer thereof and / or a veterinarily acceptable salt thereof for use in treating or protecting an animal from infestation or infection by invertebrate pests.